Intestinal Research

Original Articles

Microbiota

Characterization of the fecal microbiota differs between age groups in Koreans: Sun-Young Kook, Yunjeong Kim, Ben Kang, Yon Ho Choe, Young-Ho Kim, Seokjin Kim; Intest Res 2018;16(2):246-254. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.246

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Tens of trillions of microorganisms constitute the gut microbiota of the human body. The microbiota plays a critical role in maintaining host immunity and metabolism. Analyses of the gut microbial composition in Korea are limited to a few studies consisting of small sample sizes. To investigate the gut microbial community in a large sample of healthy Koreans, we analyzed the 16S ribosomal RNA of 4 representative bacterial genera Lactobacillus, Bifidobacterium, Bacteroides, and Clostridium.

Methods

A total of 378 DNA samples extracted from 164 infants and 214 adults were analyzed using quantitative real-time polymerase chain reaction.

Results

Analysis of 16S ribosomal RNA of 4 representative bacterial genera Lactobacillus, Bifidobacterium, Bacteroides, and Clostridium showed that the gut microbiota in infants had higher relative abundances of Bifidobacterium and Lactobacillus than that in adults, which was dominated by Bacteroides and Clostridium.

Conclusions

To the best of our knowledge, this was the first study evaluating the distinct characteristics of the microbial community of Korean infants and adults. The differences between the 2 populations suggest that external factors such as age, diet, and the environment are important contributing factors to the change in gut microbial composition during development.

Citations

Citations to this article as recorded by

Effects of Administration of Prebiotics Alone or in Combination with Probiotics on In Vitro Fermentation Kinetics, Malodor Compound Emission and Microbial Community Structure in Swine
Maro Lee, Yeonjae Choi, Joel Bayo, Andrew Wange Bugenyi, Yangseon Kim, Jaeyoung Heo
Fermentation.2023; 9(8): 716. CrossRef
Statistical Optimization of Culture Conditions for Lactobacillus Strains using Response Surface Methodology
Young Min Hwang, Hee-Seok Lee
Journal of Food Hygiene and Safety.2023; 38(5): 338. CrossRef
The correlation of the fecal microbiome with the biochemical profile during menopause: a Brazilian cohort study
Thayane Christine Alves da Silva, Jennefer Aparecida dos Santos Gonçalves, Laura Alves Cota e Souza, Angélica Alves Lima, R. Guerra-Sá
BMC Women's Health.2022;[Epub] CrossRef
The Effect of Kefir Supplementation on Improving Human Endurance Exercise Performance and Antifatigue
Mon-Chien Lee, Wei-Lun Jhang, Chia-Chia Lee, Nai-Wen Kan, Yi-Ju Hsu, Chin-Shan Ho, Chun-Hao Chang, Yi-Chen Cheng, Jin-Seng Lin, Chi-Chang Huang
Metabolites.2021; 11(3): 136. CrossRef
Space, time and captivity: quantifying the factors influencing the fecal microbiome of an alpine ungulate
Sarah E Haworth, Kevin S White, Steeve D Côté, Aaron B A Shafer
FEMS Microbiology Ecology.2019;[Epub] CrossRef
Isolation and characterization of five novel probiotic strains from Korean infant and children faeces
Sun-Young Kook, Eui-Chun Chung, Yaelim Lee, Dong Wan Lee, Seokjin Kim, Sudarshan Kumar
PLOS ONE.2019; 14(10): e0223913. CrossRef
Characteristics of Faecal Microbiota in Korean Patients withClostridioides difficile-associated Diarrhea
Yong Duk Jeon, Hea Won Ann, Woon Ji Lee, Jun Hyoung Kim, Hye Seong, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Joon Sup Yeom, Dongeun Yong, Kyungwon Lee, Jun Yong Choi
Infection & Chemotherapy.2019; 51(4): 365. CrossRef

7,970 View
176 Download
6 Web of Science
7 Crossref

IBD

Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies: Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi; Intest Res 2018;16(2):233-245. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.233

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Tofacitinib is an oral, small-molecule Janus kinase inhibitor being investigated for ulcerative colitis (UC). In OCTAVE Induction 1 and 2, patients with moderately to severely active UC received placebo or tofacitinib 10 mg twice daily (BID) for 8 weeks. Clinical responders in OCTAVE Induction were re-randomized to 52 weeks' therapy with placebo, tofacitinib 5 mg BID, or tofacitinib 10 mg BID.

Methods

We conducted post-hoc efficacy and safety analyses of East Asian patients in OCTAVE Induction 1 and 2 and OCTAVE Sustain.

Results

A total of 121 East Asian (Japan, Korea, and Taiwan) patients were randomized in OCTAVE Induction 1 and 2 (placebo, n=26; tofacitinib 10 mg BID, n=95), and 63 in OCTAVE Sustain (placebo, n=20; tofacitinib 5 mg BID, n=22; tofacitinib 10 mg BID, n=21). At week 8 of OCTAVE Induction 1 and 2, 18.9% of patients (18/95) achieved remission with tofacitinib 10 mg BID versus 3.8% (1/26) with placebo. In OCTAVE Sustain, the week 52 remission rates were 45.5% (10/22), 47.6% (10/21), and 15.0% (3/20) with 5 mg BID, 10 mg BID, and placebo, respectively. Adverse event rates were similar between groups in OCTAVE Induction and numerically higher with tofacitinib in OCTAVE Sustain. Serious adverse event rates were similar across groups in all studies. Infections were numerically more frequent with tofacitinib than placebo. Increases in serum lipid levels were observed with tofacitinib.

Conclusions

In East Asian patients with UC, tofacitinib demonstrated numerically greater efficacy versus placebo as induction and maintenance therapy, with a safety profile consistent with the global study population. ClinicalTrials.gov: NCT01465763; NCT01458951; NCT01458574.

Citations

Citations to this article as recorded by

Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis
Jian Zeng, Zhong Wang, Xiao-Jun Yang
European Journal of Clinical Pharmacology.2022; 78(7): 1069. CrossRef
Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef
Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open
Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim, Byong Duk Ye, Shoko Arai, Masato Hoshi, Hirotoshi Yuasa, Junichi Tabira, Shigeyuki Toyoizumi, Nanzhi Shi, Joon‐suk Woo, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2022; 37(10): 1884. CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis
Brittany N. Palasik, Hongmei Wang
Journal of Pharmacy Practice.2021; 34(6): 913. CrossRef
Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Toshifumi Hibi, Isao Kamae, Philippe Pinton, Lyann Ursos, Ryuichi Iwakiri, Greg Hather, Haridarshan Patel
Intestinal Research.2021; 19(1): 53. CrossRef
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intestinal Research.2021; 19(4): 386. CrossRef
Post-inflammatory Abdominal Pain in Patients with Inflammatory Bowel Disease During Remission: A Comprehensive Review
Kazuya Takahashi, Iman Geelani Khwaja, Jocelyn Rachel Schreyer, David Bulmer, Madusha Peiris, Shuji Terai, Qasim Aziz
Crohn's & Colitis 360.2021;[Epub] CrossRef
Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis
Keiichi Tominaga, Mimari Kanazawa, Kazuhiro Takenaka, Takanao Tanaka, Takeshi Sugaya, Koh Fukushi, Yuka Takagi, Kazunori Nagashima, Keiichiro Abe, Naoya Izawa, Kohei Tsuchida, Makoto Iijima, Kenichi Goda, Hidetsugu Yamagishi, Atsushi Irisawa
Clinical Journal of Gastroenterology.2020; 13(3): 340. CrossRef
Interleukin 23 and autoimmune diseases: current and possible future therapies
Ahmad Ismail Khaled Abdo, Gee Jun Tye
Inflammation Research.2020; 69(5): 463. CrossRef
A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis
Keiichi Tominaga, Mimari Kanazawa, Takanao Tanaka, Shunsuke Kojimahara, Takeshi Sugaya, Shoko Watanabe, Akira Yamamiya, Yuichi Majima, Makoto Iijima, Kenichi Goda, Atsushi Irisawa
Medicina.2020; 56(11): 595. CrossRef
Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas
José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda
Medicina Clínica.2019; 152(9): 353. CrossRef
Interleukin-13: A promising therapeutic target for autoimmune disease
Yan-Mei Mao, Chan-Na Zhao, Jing Leng, Rui-Xue Leng, Dong-Qing Ye, Song Guo Zheng, Hai-Feng Pan
Cytokine & Growth Factor Reviews.2019; 45: 9. CrossRef
JAK-STAT inhibitors for the treatment of immunomediated diseases
José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda
Medicina Clínica (English Edition).2019; 152(9): 353. CrossRef
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
Ferdinando D’Amico, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef
Inhibitors of the Janus Kinases
Elisabetta Antonelli, Gabriele Torti, Gabrio Bassotti
Journal of Clinical Gastroenterology.2019; 53(9): 635. CrossRef
Novel oral-targeted therapies for mucosal healing in ulcerative colitis
Elisabetta Antonelli, Vincenzo Villanacci, Gabrio Bassotti
World Journal of Gastroenterology.2018; 24(47): 5322. CrossRef

7,978 View
203 Download
20 Web of Science
19 Crossref

IBD

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study: Akihiro Koga, Toshiyuki Matsui, Noritaka Takatsu, Yasumichi Takada, Masahiro Kishi, Yutaka Yano, Takahiro Beppu, Yoichiro Ono, Kazeo Ninomiya, Fumihito Hirai, Takashi Nagahama, Takashi Hisabe, Yasuhiro Takaki, Kenshi Yao, Hirotsugu Imaeda, Akira Andoh; Intest Res 2018;16(2):223-232. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.223

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could become a predictor of mucosal healing (MH) (Study 2).

Methods

Study 1 was conducted in 108 patients, including those with LOR and remission to compare ATI and TLI in discriminating the 2 conditions based on receiver operating characteristic (ROC) curve analyses. Study 2 involved 35 patients who were evaluated endoscopically.

Results

In Study 1, there were no differences between the 2 assays in ROC curve analyses; the TLI cutoff value for LOR was 2.6 µg/mL (sensitivity, 70.9%; specificity, 79.2%), and the ATI cutoff value was 4.9 µg/mL (sensitivity, 65.5%; specificity, 67.9%). The AUROC (area under the ROC curve) of TLI was greater than that of ATI. AUROC was useful for discriminating between the 2 conditions. In Study 2, the TLI was significantly higher in the colonic MH group than in the non-MH group (2.7 µg/mL vs. 0.5 µg/mL, P=0.032).

Conclusions

TLI is better than ATI for clinically diagnosing LOR, and a correlation was observed between TLI and colonic MH.

Citations

Citations to this article as recorded by

Is infliximab therapy currently relevant in patients with inflammatory bowel diseases? (review)
T. L. Alexandrov, B. A. Vykova
Koloproktologia.2024; 23(2): 173. CrossRef
Mucosal and Transmural Healing and Long-term Outcomes in Crohn’s Disease
Bruce E Sands, Silvio Danese, J Casey Chapman, Khushboo Gurjar, Stacy Grieve, Deepika Thakur, Jenny Griffith, Namita Joshi, Kristina Kligys, Axel Dignass
Inflammatory Bowel Diseases.2024;[Epub] CrossRef
Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients—a preliminary study
Mayte Buchbender, Jakob Fehlhofer, Peter Proff, Tobias Möst, Jutta Ries, Matthias Hannig, Markus F. Neurath, Madline Gund, Raja Atreya, Marco Kesting
Clinical Oral Investigations.2022; 26(2): 1217. CrossRef
Microbiota and Drug Response in Inflammatory Bowel Disease
Martina Franzin, Katja Stefančič, Marianna Lucafò, Giuliana Decorti, Gabriele Stocco
Pathogens.2021; 10(2): 211. CrossRef
Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
Eran Zittan, A. Hillary Steinhart, Pavel Goldstein, Raquel Milgrom, Ian M. Gralnek, Mark S. Silverberg
Clinical and Translational Gastroenterology.2021; 12(10): e00401. CrossRef
Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
So Yoon Choi, Young Ok Choi, Yon Ho Choe, Ben Kang
Journal of Korean Medical Science.2020;[Epub] CrossRef
Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases
Ana B. Grinman, Maria das Graças C. de Souza, Eliete Bouskela, Ana Teresa P. Carvalho, Heitor S. P. de Souza
Medicine.2020; 99(10): e19359. CrossRef
Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
Gyeol Seong, Namil Kim, Je-Gun Joung, Eun Ran Kim, Dong Kyung Chang, Jongsik Chun, Sung Noh Hong, Young-Ho Kim
Microorganisms.2020; 8(6): 874. CrossRef
Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events
Mitchell R. K. L. Lie, Emma Paulides, C. Janneke van der Woude
International Journal of Colorectal Disease.2020; 35(8): 1489. CrossRef
Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment
Ting Feng, Baili Chen, Bella Ungar, Yun Qiu, Shenghong Zhang, Jinshen He, Sinan Lin, Yao He, Zhirong Zeng, Shomron Ben-Horin, Minhu Chen, Ren Mao
Inflammatory Bowel Diseases.2019; 25(11): 1813. CrossRef
Mucosal healing in inflammatory bowel disease: Expanding horizon
Jimil Shah, Manik Lal Thakur, Usha Dutta
Indian Journal of Gastroenterology.2019; 38(2): 98. CrossRef

6,780 View
75 Download
10 Web of Science
11 Crossref

IBD

Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis: Ki Hwan Song, Eun Soo Kim, Yoo Jin Lee, Byung Ik Jang, Kyeong Ok Kim, Sang Gyu Kwak, Hyun Seok Lee; Intest Res 2018;16(2):216-222. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.216

Abstract PDF PubReader ePub

Background/Aims

This study aimed to compare the clinical characteristics and management patterns of inflammatory bowel disease (IBD) patients in a secondary hospital (SH) with those in tertiary referral centers (TRC).

Methods

Data from IBD patients in SH and 2 TRCs were retrospectively reviewed. The cumulative thiopurine use rate was compared between hospitals after controlling for different baseline characteristics using propensity score matching.

Results

Among the total of 447 patients with IBD, 178 Crohn's disease (CD) and 269 ulcerative colitis (UC) patients were included. Regarding initial CD symptoms, patients from SH were more likely to show perianal symptoms, such as anal pain or discharge (56.6% vs. 34.3%, P=0.003), whereas those from TRCs more often had luminal symptoms, such as abdominal pain (54.9% vs. 17.1%, P<0.001), diarrhea (44.1% vs. 18.4%, P<0.001), and body weight loss (9.8% vs. 1.3%, P=0.025). Complicating behaviors, such as stricturing and penetrating, were significantly higher in TRCs, while perianal disease was more common in SH. Ileal location was more frequently observed in TRCs. For UC, SH had a more limited extent of disease (proctitis 58.8% vs. 21.2%, P<0.001). The cumulative azathioprine use rate in SH was significantly lower than that in TRCs in both CD and UC patients after controlling for disease behavior, location, and perianal disease of CD and extent of UC.

Conclusions

The clinical characteristics and management of the IBD patients in SH were substantially different from those in TRCs. Thiopurine treatment was less commonly used for SH patients.

Citations

Citations to this article as recorded by

Early course of newly diagnosed moderate‐to‐severe ulcerative colitis in Korea: Results from a hospital‐based inception cohort study (MOSAIK)
Jin Young Yoon, Jae Myung Cha, Chang Kyun Lee, Young Sook Park, Kyu Chan Huh, Jeong Eun Shin, You Sun Kim, Chang Soo Eun, Soon Man Yoon, Jae Hee Cheon, Young Soo Park, Byong Duk Ye, YoungJa Lee, Youngdoe Kim, Hyo Jong Kim
Journal of Gastroenterology and Hepatology.2021; 36(8): 2149. CrossRef
VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study
Catherine Le Berre, Mathurin Flamant, Guillaume Bouguen, Laurent Siproudhis, Marie Dewitte, Nina Dib, Elodie Cesbron-Metivier, Thomas Goronflot, Matthieu Hanf, Pierre-Antoine Gourraud, Elise Kerdreux, Alexandra Poinas, Arnaud Bourreille, Caroline Trang-Po
Journal of Crohn's and Colitis.2020; 14(11): 1512. CrossRef

5,508 View
55 Download
2 Web of Science
2 Crossref

Endoscopy

Clinical outcomes of surveillance colonoscopy for patients with sessile serrated adenoma: Sung Jae Park, Hyuk Yoon, In Sub Jung, Cheol Min Shin, Young Soo Park, Na Young Kim, Dong Ho Lee; Intest Res 2018;16(1):134-141. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.134

Abstract PDF PubReader ePub

Background/Aims

Sessile serrated adenomas (SSAs) are known to be precursors of colorectal cancer (CRC). The proper interval of follow-up colonoscopy for SSAs is still being debated. We sought to determine the proper interval of colonoscopy surveillance in patients diagnosed with SSAs in South Korea.

Methods

We retrospectively reviewed the medical records of patients diagnosed with SSAs who received 1 or more follow-up colonoscopies. The information reviewed included patient baseline characteristics, SSA characteristics, and colonoscopy information.

Results

From January 2007 to December 2011, 152 SSAs and 8 synchronous adenocarcinomas were identified in 138 patients. The mean age of the patients was 62.2 years and 60.1% patients were men. SSAs were located in the right colon (i.e., from the cecum to the hepatic flexure) in 68.4% patients. At the first follow-up, 27 SSAs were identified in 138 patients (right colon, 66.7%). At the second follow-up, 6 SSAs were identified in 65 patients (right colon, 66.7%). At the 3rd and 4th follow-up, 21 and 11 patients underwent colonoscopy, respectively, and no SSAs were detected. The total mean follow-up duration was 33.9 months. The mean size of SSAs was 8.1±5.0 mm. SSAs were most commonly found in the right colon (126/185, 68.1%). During annual follow-up colonoscopy surveillance, no cancer was detected.

Conclusions

Annual colonoscopy surveillance is not necessary for identifying new CRCs in all patients diagnosed with SSAs. In addition, the right colon should be examined more carefully because SSAs occur more frequently in the right colon during initial and follow-up colonoscopies.

Citations

Citations to this article as recorded by

Endoscopic Diagnosis, Treatment, and Follow-up of Serrated Polyps
Duk Hwan Kim
Journal of Digestive Cancer Research.2023; 11(1): 30. CrossRef
Features associated with high‐risk sessile serrated polyps at index and follow‐up colonoscopy
Shahzaib Anwar, Charles Cock, Joanne Young, Graeme P Young, Rosie Meng, Kalindra Simpson, Michelle Coats, Junming Huang, Peter Bampton, Robert Fraser, Erin L Symonds
Journal of Gastroenterology and Hepatology.2021; 36(6): 1620. CrossRef
Descriptive epidemiological study of South African colorectal cancer patients at a Johannesburg Hospital Academic institution
Michelle McCabe, Yvonne Perner, Rindidzani Magobo, Sheefa Mirza, Clement Penny
JGH Open.2020; 4(3): 360. CrossRef
Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia
Xinwei Hua, Polly A. Newcomb, Jessica Chubak, Rachel C. Malen, Rebecca Ziebell, Aruna Kamineni, Lee-Ching Zhu, Melissa P. Upton, Michelle A. Wurscher, Sushma S. Thomas, Hana Newman, Sheetal Hardikar, Andrea N. Burnett-Hartman
Cancer Causes & Control.2020; 31(7): 631. CrossRef
The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia
Andrea N. Burnett-Hartman, Jessica Chubak, Xinwei Hua, Rebecca Ziebell, Aruna Kamineni, Lee-Ching Zhu, Melissa P. Upton, Rachel C. Malen, Sheetal Hardikar, Polly A. Newcomb
Cancer Causes & Control.2019; 30(9): 979. CrossRef
Surveillance colonoscopy in patients with sessile serrated adenoma
Ji Hyung Nam, Hyoun Woo Kang
Intestinal Research.2018; 16(3): 502. CrossRef

12,084 View
69 Download
5 Web of Science
6 Crossref

Endoscopy

Three-year colonoscopy surveillance after polypectomy in Korea: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter prospective study: Won Seok Choi, Dong Soo Han, Chang Soo Eun, Dong Il Park, Jeong-Sik Byeon, Dong-Hoon Yang, Sung-Ae Jung, Sang Kil Lee, Sung Pil Hong, Cheol Hee Park, Suck-Ho Lee, Jeong-Seon Ji, Sung Jae Shin, Bora Keum, Hyun Soo Kim, Jung Hye Choi, Sin-Ho Jung; Intest Res 2018;16(1):126-133. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.126

Abstract PDF PubReader ePub

Background/Aims

Colonoscopic surveillance is currently recommended after polypectomy owing to the risk of newly developed colonic neoplasia. However, few studies have investigated colonoscopy surveillance in Asia. This multicenter and prospective study was undertaken to assess the incidence of advanced adenoma based on baseline adenoma findings at 3 years after colonoscopic polypectomy.

Methods

A total of 1,323 patients undergoing colonoscopic polypectomy were prospectively assigned to 3-year colonoscopy surveillance at 11 tertiary endoscopic centers. Relative risks for advanced adenoma after 3 years were calculated according to baseline adenoma characteristics.

Results

Among 1,323 patients enrolled, 387 patients (29.3%) were followed up, and the mean follow-up interval was 31.0±9.8 months. The percentage of patients with advanced adenoma on baseline colonoscopy was higher in the surveillance group compared to the non-surveillance group (34.4% vs. 25.7%). Advanced adenoma recurrence was observed in 17 patients (4.4%) at follow-up. The risk of advanced adenoma recurrence was 2 times greater in patients with baseline advanced adenoma than in those with baseline non-advanced adenoma, though the difference was not statistically significant (6.8% [9/133] vs. 3.1% [8/254], P=0.09). Advanced adenoma recurrence was observed only in males and in subjects aged ≥50 years. In contrast, adenoma recurrence was observed in 187 patients (48.3%) at follow-up. Male sex, older age (≥50 years), and multiple adenomas (≥3) at baseline were independent risk factors for adenoma recurrence.

Conclusions

A colonoscopy surveillance interval of 3 years in patients with baseline advanced adenoma can be considered appropriate.

Citations

Citations to this article as recorded by

When should patients take simethicone orally before colonoscopy for avoiding bubbles: A single-blind, randomized controlled study
Woohyuk Jung, Gyu Man Oh, Jae Hyun Kim, Youn Jung Choi, Min Young Son, Kyoungwon Jung, Sung Eun Kim, Won Moon, Moo In Park, Seun Ja Park
Medicine.2023; 102(19): e33728. CrossRef
Comparison of the efficacy and safety between oral sulfate tablet and polyethylene glycol for bowel preparation before colonoscopy according to age
Jae Hyun Kim, Yong Eun Park, Tae Oh Kim, Jongha Park, Gyu Man Oh, Won Moon, Seun Ja Park
Medicine.2022; 101(27): e29884. CrossRef
Optimization of the surveillance strategy in patients with colorectal adenomas: A combination of clinical parameters and index colonoscopy findings
Chan Hyuk Park, Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
Journal of Gastroenterology and Hepatology.2021; 36(4): 974. CrossRef
Postgastrectomy gastric cancer patients are at high risk for colorectal neoplasia: a case control study
Tae-Geun Gweon, Kyu-Tae Yoon, Chang Hyun Kim, Jin-Jo Kim
Intestinal Research.2021; 19(2): 239. CrossRef
Risk of developing metachronous advanced colorectal neoplasia after resection of low-risk diminutive versus small adenomas
Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
Gastrointestinal Endoscopy.2020; 91(3): 622. CrossRef
Optimal Colonoscopic Surveillance Interval After Normal Baseline Screening Colonoscopy
Jian Dong, Minman Wu, Jiarong Miao, Rana Sami Ullah Khan, Tao Zhi, Tianmei Zhang, Xue Li, Yashi Peng, Gang Yang, Qiong Nan
Gastroenterology Nursing.2020; 43(3): 225. CrossRef
Comparative systematic review and meta-analysis of 1- to 5-mm versus 6- to 9-mm adenomas on the risk of metachronous advanced colorectal neoplasia
Yoon Suk Jung, Tae Jun Kim, Eunwoo Nam, Chan Hyuk Park
Gastrointestinal Endoscopy.2020; 92(3): 692. CrossRef
Appropriate Surveillance Interval after Colonoscopic Polypectomy in Patients Younger than 50 Years
Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
Journal of Korean Medical Science.2019;[Epub] CrossRef
Impact of obesity and metabolic abnormalities on the risk of metachronous colorectal neoplasia after polypectomy in men
Nam Hee Kim, Yoon Suk Jung, Jung Ho Park, Dong Il Park, Chong Il Sohn
Journal of Gastroenterology and Hepatology.2019; 34(9): 1504. CrossRef
What Is Appropriate Upper Endoscopic Interval Among Dyspeptic Patients With Previously Normal Endoscopy? A Multicenter Study With Bayesian Change Point Analysis
Jong Wook Kim, Kee Wook Jung, Joong Goo Kwon, Jung Bok Lee, Jong Kyu Park, Ki Bae Bang, Chung Hyun Tae, Jung Hwan Oh
Journal of Neurogastroenterology and Motility.2019; 25(4): 544. CrossRef
Risk of Developing Metachronous Advanced Colorectal Neoplasia After Polypectomy in Patients With Multiple Diminutive or Small Adenomas
Nam Hee Kim, Yoon Suk Jung, Mi Yeon Lee, Jung Ho Park, Dong Il Park, Chong Il Sohn
American Journal of Gastroenterology.2019; 114(10): 1657. CrossRef

9,164 View
81 Download
12 Web of Science
11 Crossref

Colorectal neoplasia

Topographic, histological and molecular study of aberrant crypt foci identified in human colon in different clinical groups: Shouriyo Ghosh, Brijnandan Gupta, Pavan Verma, Sreenivas Vishnubathla, Sujoy Pal, Nihar R Dash, Siddhartha Datta Gupta, Prasenjit Das; Intest Res 2018;16(1):116-125. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.116

Abstract PDF PubReader ePub

Background/Aims

Aberrant crypt foci (ACF) are early microscopic lesions of the colonic mucosa, which can be detected by magnified chromoendoscopy. Herein, we have investigated whether ACF identified in different clinical groups can be differentiated based on their characteristics.

Methods

Macroscopically unremarkable mucosal flaps were collected from 270 fresh colectomies and divided into 3 clinical groups: colorectal carcinoma (group A), disease controls having known pre-neoplastic potential (group Bc), and disease controls without risk of carcinoma development (group Bn). Topographic and histologic analysis, immunohistochemistry, and molecular studies (high-resolution melt curve analysis, real-time polymerase chain reaction, and Sanger sequencing) were conducted for certain neoplasia-associated markers.

Results

ACF were seen in 107 cases, out of which 72 were left colonic ACF and 35 right colonic ACF (67.2% vs. 32.7%, P=0.02). The overall density of left colonic ACF was 0.97/cm, which was greater than the right colonic ACF density of 0.81/cm. Hypercrinia was present in 41 out of 72 left colonic ACF and in 14 out of 35 right colonic ACF (P=0.01). Immunohistochemical expression of p53 was also greater in left colonic ACF than in right colonic ACF (60.5% vs. 38.2%, P=0.03). However, ACF identified among the 3 clinical groups did not show any distinguishing topographic, histological, or genetic changes.

Conclusions

Left colonic ACF appear to be high-risk based on their morphological and prototypic tumor marker signature. ACF identified in different clinical groups do not show significant genotypic or topographic differences. Further detailed genetic studies are required to elucidate them further.

Citations

Citations to this article as recorded by

Methylation study of tumor suppressor genes in human aberrant crypt foci, colorectal carcinomas, and normal colon
Jayati Sarangi, Prasenjit Das, Aijaz Ahmad, Mohamed Sulaiman, Shouriyo Ghosh, Brijnandan Gupta, Rajesh Panwar, Sujoy Pal, Rajni Yadav, Vineet Ahuja, Sudip Sen, Asish D. Upadhyay, Nihar R. Dash, Atul Sharma, Siddhartha D. Gupta
Journal of Cancer Research and Therapeutics.2024; 20(1): 268. CrossRef

7,298 View
68 Download
1 Web of Science
1 Crossref

Infection

Rapid and accurate diagnosis of Clostridium difficile infection by real-time polymerase chain reaction: Pil Hun Song, Jung Hwa Min, You Sun Kim, Soo Yeon Jo, Eun Jin Kim, Kyung Jin Lee, Jeonghun Lee, Hyun Sung, Jeong Seop Moon, Dong Hee Whang; Intest Res 2018;16(1):109-115. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.109

Abstract PDF PubReader ePub

Background/Aims

The incidence and severity of Clostridium difficile infection (CDI) have increased worldwide, resulting in a need for rapid and accurate diagnostic methods.

Methods

A retrospective study was conducted to compare CDI diagnosis methods between January 2014 and December 2014. The stool samples, which were obtained in presumptive CDI patients, were compared for their diagnostic accuracy and rapidity, including real-time polymerase chain reaction (PCR) of toxin genes, C. difficile toxin assay, and culture for C. difficile.

Results

A total of 207 cases from 116 patients were enrolled in this study and 117 cases (56.5%) were diagnosed as having CDI. Among the 117 cases, the sensitivities of real-time PCR, C. difficile toxin assay, and culture for C. difficile were 87.2% (102 cases; 95% CI, 80.7%–92.8%), 48.7% (57 cases; 95% CI, 41.0%–59.8%), and 65.0% (76 cases; 95% CI, 60.2%–78.5%), respectively (P<0.005). Notably, 34 cases (29.0%) were diagnosed with CDI by real-time PCR only. The time required to obtain results was 2.27 hours (136.62±82.51 minutes) for real-time PCR, 83.67 hours (5,020.66±3,816.38 minutes) for toxin assay, and 105.79 hours (6,347.68±3,331.46 minutes) for culture (P<0.005), respectively.

Conclusions

We confirmed that real-time PCR of toxin genes is the most effective diagnostic method for accurate and early diagnosis of CDI. It also helps to diagnose hypervirulent CDI, such as ribotype 027 infection.

Citations

Citations to this article as recorded by

Usefulness of Stool Multiplex Polymerase Chain Reaction Assays in Patients with Acute Diarrhea
Seo Hyun Kim, You Sun Kim, Seung Hyuk Kim, Won Eui Yoon, Hee Jun Myung, Jeong Seop Moon, Dong Hee Whang
The Korean Journal of Gastroenterology.2022; 79(3): 118. CrossRef
Persistent Leg Drainage in a Pediatric Trauma Patient
Ashley Howard, Michelle R. Rychalsky, Thomas S. Murray
Pediatric Infectious Disease Journal.2021; 40(6): 597. CrossRef
Real-Time Detection and Motion Recognition of Human Moving Objects Based on Deep Learning and Multi-Scale Feature Fusion in Video
Meimei Gong, Yiming Shu
IEEE Access.2020; 8: 25811. CrossRef
Temporal change of risk factors in hospital-acquired Clostridioides difficile infection using time-trend analysis
Jiyoun Song, Bevin Cohen, Philip Zachariah, Jianfang Liu, Elaine L. Larson
Infection Control & Hospital Epidemiology.2020; 41(9): 1048. CrossRef
Incidence and Characteristics ofClostridioides difficileInfection in Children
Heera Jeong, Ji-Man Kang, Jong Gyun Ahn
Pediatric Infection & Vaccine.2020; 27(3): 158. CrossRef
RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
Jung Hoon Song, You Sun Kim
Gut and Liver.2019; 13(1): 16. CrossRef
Is Clostridium difficile infection a real threat in patients with ulcerative colitis? A prospective, multicenter study in Korea
Dae Bum Kim, Kang-Moon Lee, Sang Hyoung Park, You Sun Kim, Eun Soo Kim, Jun Lee, Sung-Ae Jung, Geom Seog Seo, Ji Min Lee
Intestinal Research.2018; 16(2): 267. CrossRef

8,178 View
91 Download
7 Web of Science
7 Crossref

Colorectal neoplasia

An analysis of dietary fiber and fecal fiber components including pH in rural Africans with colorectal cancer: Mohammed Faruk, Sani Ibrahim, Ahmed Adamu, Abdulmumini Hassan Rafindadi, Yahaya Ukwenya, Yawale Iliyasu, Abdullahi Adamu, Surajo Mohammed Aminu, Mohammed Sani Shehu, Danladi Amodu Ameh, Abdullahi Mohammed, Saad Aliyu Ahmed, John Idoko, Atara Ntekim, Aishatu Maude Suleiman, Khalid Zahir Shah, Kasimu Umar Adoke; Intest Res 2018;16(1):99-108. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.99

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Colorectal cancer (CRC) is now a major public health problem with heavy morbidity and mortality in rural Africans despite the lingering dietary fiber-rich foodstuffs consumption. Studies have shown that increased intake of dietary fiber which contribute to low fecal pH and also influences the activity of intestinal microbiota, is associated with a lowered risk for CRC. However, whether or not the apparent high dietary fiber consumption by Africans do not longer protects against CRC risk is unknown. This study evaluated dietary fiber intake, fecal fiber components and pH levels in CRC patients.

Methods

Thirty-five subjects (CRC=21, control=14), mean age 45 years were recruited for the study. A truncated food frequency questionnaire and modified Goering and Van Soest procedures were used.

Results

We found that all subjects consumed variety of dietary fiber-rich foodstuffs. There is slight preponderance in consumption of dietary fiber by the control group than the CRC patients. We also found a significant difference in the mean fecal neutral detergent fiber, acid detergent fiber, hemicellulose, cellulose and lignin contents from the CRC patients compared to the controls (P<0.05). The CRC patients had significantly more fecal pH level than the matched apparently healthy controls (P=0.017).

Conclusions

The identified differences in the fecal fiber components and stool pH levels between the 2 groups may relate to CRC incidence and mortality in rural Africans. There is crucial need for more hypothesis-driven research with adequate funding on the cumulative preventive role of dietary fiber-rich foodstuffs against colorectal cancer in rural Africans “today.”

Citations

Citations to this article as recorded by

Effect of three modification methods on physical and functional properties of flaxseed cake dietary fiber
Yanxiong Huo, Yongwang Niu, Saisai Feng, Liangliang Zhang, Jianguo Xu, Qingping Hu
LWT.2024; 198: 116076. CrossRef
Prevotella enterotype associates with diets supporting acidic faecal pH and production of propionic acid by microbiota
Signe Adamberg, Kaarel Adamberg
Heliyon.2024; 10(10): e31134. CrossRef
Validating a semi-quantitative food frequency questionnaire to assess regional diet in a study of cancer in South West Nigeria
Marguerite L. Samson, Noah C. Peeri, Olusegun Isaac Alatise, Kelli O’Connell, Avinash Sharma, Samson Gbenga Ogunleye, Adewale A. Aderounmu, Olalekan Olasehinde, Akinjide Olurotimi Ogundokun, Abiodun Victor Ikujenlola, Adesegun Fatusi, T. Peter Kingham, Me
Cancer Causes & Control.2023; 34(6): 495. CrossRef
Experimental Capacity of Human Fecal Microbiota to Degrade Fiber and Produce Short-Chain Fatty Acids Is Associated with Diet Quality and Anthropometric Parameters
Anna M. Malinowska, Malgorzata Majcher, Guido JEJ. Hooiveld, Hanna Przydatek, Marta Szaban, Agata Kurowiecka, Marcin Schmidt
The Journal of Nutrition.2023; 153(10): 2827. CrossRef
Perioperative Factors Affecting the Healing of Rectovaginal Fistula
Małgorzata Satora, Klaudia Żak, Karolina Frankowska, Marcin Misiek, Rafał Tarkowski, Marcin Bobiński
Journal of Clinical Medicine.2023; 12(19): 6421. CrossRef
The effects of enzymatic modification on the functional ingredient - Dietary fiber extracted from potato residue
Qianyun Ma, Ziye Ma, Wenxiu Wang, Jianlou Mu, Yaqiong Liu, Jie Wang, Letitia Stipkovits, Xiaodan Hui, Gang Wu, Jianfeng Sun
LWT.2022; 153: 112511. CrossRef
Dietary Intake and Cancer in Sub-Saharan Africa: A Critical Review of Epidemiological Studies
Galya Bigman, Linda Otieno, Sally N. Adebamowo, Clement Adebamowo
Nutrition and Cancer.2022; 74(8): 2803. CrossRef
Evaluation of graded levels of corn-fermented protein on stool quality, apparent nutrient digestibility, and palatability in healthy adult cats
Logan R Kilburn-Kappeler, Krystina A Lema Almeida, Charles G Aldrich
Journal of Animal Science.2022;[Epub] CrossRef
The colorectal cancer-associated faecal microbiome of developing countries resembles that of developed countries
Caroline Young, Henry M. Wood, Ramakrishnan Ayloor Seshadri, Pham Van Nang, Carlos Vaccaro, Luis Contreras Melendez, Mayilvahanan Bose, Mai Van Doi, Tamara Alejandra Piñero, Camilo Tapia Valladares, Julieta Arguero, Alba Fuentes Balaguer, Kelsey N. Thomps
Genome Medicine.2021;[Epub] CrossRef
Patterns of Early-Onset Colorectal Cancer Among Nigerians and African Americans
Andreana N. Holowatyj, Aishatu Suleiman Maude, Halimatu Sadiya Musa, Ahmed Adamu, Sani Ibrahim, Adamu Abdullahi, Muhammad Manko, Sirajo Mohammed Aminu, Abdullahi Mohammed, John Idoko, Yahaya Ukwenya, John Carpten, Paulette D. Chandler, Heather Hampel, Moh
JCO Global Oncology.2020; (6): 1647. CrossRef

6,761 View
81 Download
10 Web of Science
10 Crossref

IBD

Distribution of cytomegalovirus genotypes among ulcerative colitis patients in Okinawa, Japan: Saifun Nahar, Akira Hokama, Atsushi Iraha, Tetsuya Ohira, Tetsu Kinjo, Tetsuo Hirata, Takeshi Kinjo, Gretchen L. Parrott, Jiro Fujita; Intest Res 2018;16(1):90-98. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.90

Abstract PDF PubReader ePub

Background/Aims

To determine the prevalence of glycoprotein B (gB), glycoprotein N (gN), and glycoprotein H (gH) genotypes of human cytomegalovirus (HCMV) superimposed on ulcerative colitis (UC) patients in Japan.

Methods

Four archived stool samples and 7-archived extracted DNA from stool samples of 11 UC patients with positive multiplex polymerase chain reaction (PCR) results for HCMV were used UL55 gene encoding gB, UL73 gene encoding gN, and UL75 gene encoding gH were identified by PCR. Genotypes of gB and glycoprotein N were determined by sequencing.

Results

Among 11 samples, 8 samples were amplified through PCR. gB, gN, and gH genotypes were successfully detected in 3 of 8 (37.5%), 4 of 8 (50%), and 8 of 8 (100%), respectively. The distribution of gB and gN genotypes analyzed through phylogenetic analysis were as follows: gB1 (2/3, 66.7%), gB3 (1/3, 33.3%), gN3a (2/4, 50%), and gN3b (2/4, 50%). Other gB genotypes (gB2 and gB4) and gN genotypes (gN1, gN2, and gN4) were not detected in this study. Out of successfully amplified 8 samples of gH genotype, gH1 and gH2 were distributed in 12.5% and 75% samples, respectively. Only 1 sample revealed mixed infection of gH genotype. The distribution of gH1 and gH2 differed significantly (1:6, P<0.05) in UC patients. The distribution of single gH genotype also revealed significant difference in UC patients who were treated with immunosuppressive drug (P<0.05).

Conclusions

In this study, gB1, gN3, and gH2 gene were determined as the most frequently observed genotypes in UC patients, which suggest that there might be an association between these genotypes of HCMV and UC.

Citations

Citations to this article as recorded by

Significance of Cytomegalovirus gB Genotypes in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation: Insights from a Single-Centre Investigation
Tamara Vasiljevic, Marko Jankovic, Ana Tomic, Ida Bakrac, Stefan Radenovic, Danijela Miljanovic, Aleksandra Knezevic, Tanja Jovanovic, Irena Djunic, Milena Todorovic-Balint
Pharmaceuticals.2024; 17(4): 428. CrossRef
Cytomegalovirus Genotype Distribution among Congenital and Perinatal Infected Patients with CMV-Associated Thrombocytopenia
Hongbo Hu, Wenwen Peng, Qiaoying Peng, Ying Cheng
Fetal and Pediatric Pathology.2022; 41(1): 77. CrossRef
Cytomegalovirus Genotype and Virulence in Infants with Congenital Infection
Hong-bo Hu, Jian-gang Wu, Jian-jun Sun, Qiao-ying Peng, Xiao-peng Shang
Journal of Pediatric Infectious Diseases.2021; 16(04): 171. CrossRef
Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity
Hsuan-Yuan Wang, Sarah M. Valencia, Susanne P. Pfeifer, Jeffrey D. Jensen, Timothy F. Kowalik, Sallie R. Permar
Viruses.2021; 13(6): 1106. CrossRef
Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
Alexandre Jentzer, Pauline Veyrard, Xavier Roblin, Pierre Saint-Sardos, Nicolas Rochereau, Stéphane Paul, Thomas Bourlet, Bruno Pozzetto, Sylvie Pillet
Microorganisms.2020; 8(7): 1078. CrossRef

10,107 View
119 Download
8 Web of Science
5 Crossref

IBD

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis: Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood; Intest Res 2018;16(1):83-89. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.83

Abstract PDF PubReader ePub

Background/Aims

Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited.

Methods

Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimilars, or surgery. A retrospective analysis was conducted on patients who were treated with the adalimumab biosimilar, Exemptia. These patients were administered an induction dosing schedule of 160 mg Exemptia at week 0, 80 mg at week 2, and then 40 mg every other week from week 4 to 8. The clinical response and remission were assessed at week 8 using Mayo score.

Results

A total of 29 patients (62.1% male; mean age, 34.9 ± 9.7 years) with moderate-to-severe steroid-refractory active UC (mean disease duration, 6.3±5.1 years; pancolitis in 9 patients [31.1%]; left-sided colitis in 20 patients [68.9%]) were treated with the Exemptia induction dosing schedule. The mean Mayo score at presentation was 8.2±1.4. At week 8, clinical response was observed in 7 patients (24.1%), whereas clinical remission was observed only in 1 patient (3.5%). Among the non-responders (n=21), 4 patients required colectomy, 1 died, 1 was lost to follow-up, 10 were offered fecal microbiota transplant, 3 were administered infliximab, and 2 patients were administered cyclosporine and tacrolimus, respectively. Four patients (13.8%) developed extrapulmonary tuberculosis.

Conclusions

The adalimumab biosimilar Exemptia has limited efficacy for the attainment of clinical response and remission in moderate-to-severe steroid-refractory UC, with a significant risk of acquisition or reactivation of tuberculosis in developing countries such as India.

Citations

Citations to this article as recorded by

Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci, Antonio Cuomo, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Federica Gaiani, GianMarco Giorgetti, Maria Giovanna Graziani, Katia Lofano
Inflammatory Bowel Diseases.2023; 29(3): 376. CrossRef
Crohn’s Disease Among the Poorest Billion: Burden of Crohn’s Disease in Low- and Lower-Middle-Income Countries
Ruma Rajbhandari, Samantha Blakemore, Neil Gupta, Sara Mannan, Klejda Nikolli, Alison Yih, Laura Drown, Gene Bukhman
Digestive Diseases and Sciences.2023; 68(4): 1226. CrossRef
The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis
Arvind Chopra, Nagnath Khadke, Manjit Saluja, Toktam Kianifard, Anuradha Venugopalan, Mihir Gharia
Cureus.2023;[Epub] CrossRef
Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit
Alimentary Pharmacology & Therapeutics.2022; 55(11): 1431. CrossRef
Challenges for biosimilars: focus on rheumatoid arthritis
Muhammad Safwan Akram, Neelam Pery, Lucy Butler, Muhammad Imtiaz Shafiq, Nayab Batool, Muhammad Fayyaz ur Rehman, Luke G. Grahame-Dunn, Ali K. Yetisen
Critical Reviews in Biotechnology.2021; 41(1): 121. CrossRef
Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series
Sujay Khandpur, Prateek Sondhi, Neha Taneja, Preeti Sharma, Dayasagar Das, Alpana Sharma, Vishnubatla Sreenivas
Journal of the American Academy of Dermatology.2020; 83(1): 248. CrossRef
Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
Saurabh Kedia, Venigalla Pratap Mouli, Nagesh Kamat, Jeeva Sankar, Ashwin Ananthakrishnan, Govind Makharia, Vineet Ahuja
American Journal of Gastroenterology.2020; 115(3): 340. CrossRef
Biosimilars in inflammatory bowel disease
Saurabh Talathi, Kondal R. Kyanam Kabir Baig
Journal of Digestive Diseases.2020; 21(11): 610. CrossRef
Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis
Yuto Yamada, Yuta Ohno, Takashi Niwa, Hiroko Kato‐Hayashi, Hideki Hayashi, Takashi Ibuka, Hiroshi Araki, Tadashi Sugiyama, Masahito Shimizu, Akio Suzuki
Journal of Clinical Pharmacy and Therapeutics.2019; 44(3): 409. CrossRef
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal, Abhimanyu Nehra, Govind Makharia, Ajit Sood, Vandana Midha, Varun Gupta, Gourdas Choudhuri, Vineet Ahuja
Indian Journal of Gastroenterology.2019; 38(1): 44. CrossRef
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Marjorie Argollo, Gionata Fiorino, Daniela Gilardi, Federica Furfaro, Giulia Roda, Laura Loy, Mariangela Allocca, Laurent Peyrin-Biroulet, Silvio Danese
Current Pharmaceutical Design.2019; 25(1): 7. CrossRef

6,590 View
95 Download
13 Web of Science
11 Crossref

IBD

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease: Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada; Intest Res 2018;16(1):75-82. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.75

Abstract PDF PubReader ePub

Background/Aims

The efficacy of anti-tumor necrosis factor α (anti-TNFα) antibodies for postoperative Crohn's disease (CD) in patients who were treated with these agents prior to surgery is largely unknown.

Methods

CD patients who underwent intestinal resection and received anti-TNFα agents after surgery were divided into 2 groups according to the presence or absence of preoperative anti-TNFα treatment: anti-TNFα restart group or anti-TNFα naïve group. Endoscopic recurrence after surgery was examined according to the preoperative conditions, including administration of anti-TNFα agents before surgery.

Results

Thirty-six patients received anti-TNFα antibody after surgery: 22 in the anti-TNFα restart group and 14 in the anti-TNFα naïve group. Endoscopic recurrence after surgery was more frequently observed in the anti-TNFα restart group than in the anti-TNFα naïve group (68% vs. 14%, P<0.001). Multivariate analysis revealed the following significant risk factors of endoscopic recurrence after surgery: anti-TNF restart group (odds ratio [OR], 28.10; 95% CI, 3.08–722.00), age at diagnosis <23 years (OR, 24.30; 95% CI, 1.67–1,312.00), serum albumin concentration at surgery <3.3 g/dL (OR, 34.10; 95% CI, 1.72–2,804.00), and presence of inflammation outside of the surgical site (OR, 21.40; 95% CI, 1.02–2,150.00). Treatment intensification for patients with endoscopic recurrence in the anti-TNFα restart group showed limited responses, with only 1 of 12 patients achieving endoscopic remission.

Conclusions

The efficacy of restarting anti-TNFα antibody treatment after surgery was limited, and treatment intensification or a change to different classes of biologics should be considered for those patients.

Citations

Citations to this article as recorded by

Common Mistakes in Managing Patients with Inflammatory Bowel Disease
Javier P. Gisbert, María Chaparro
Journal of Clinical Medicine.2024; 13(16): 4795. CrossRef
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
Javier P. Gisbert, María Chaparro
Drugs.2023; 83(13): 1179. CrossRef
Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef
Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events
Mitchell R. K. L. Lie, Emma Paulides, C. Janneke van der Woude
International Journal of Colorectal Disease.2020; 35(8): 1489. CrossRef
Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry
Fiorella Cañete, Míriam Mañosa, María José Casanova, Ramiro C González-Sueyro, Jesús Barrio, Fernando Bermejo, Pilar Nos, Eva Iglesias-Flores, Esther García-Planella, José Lázaro Pérez-Calle, Raquel Vicente, Maribel Vera, Laura Ramos, Montserrat Rivero, R
Inflammatory Bowel Diseases.2019; 25(11): 1862. CrossRef
Maneuvering Clinical Pathways for Crohn’s Disease
Thomas X. Lu, Russell D. Cohen
Current Gastroenterology Reports.2019;[Epub] CrossRef
Author's Reply
Sakiko Hiraoka, Jun Kato, Hiroyuki Okada
Intestinal Research.2018; 16(2): 321. CrossRef
The old versus the new: which do you keep in postoperative Crohn's disease?
Paulo Gustavo Kotze, Christopher Ma, Miguel Regueiro, Remo Panaccione
Intestinal Research.2018; 16(2): 319. CrossRef

5,120 View
83 Download
8 Web of Science
8 Crossref

IBD

Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study: Saransh Jain, Saurabh Kedia, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Peush Sahni, Sujoy Pal, Nihar Ranjan Dash, Govind Makharia, Simon P. L. Travis, Vineet Ahuja; Intest Res 2018;16(1):69-74. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.69

Abstract PDF PubReader ePub

Background/Aims

Truelove and Witts criteria have been used to define acute severe colitis since the 1950s. However, hemoglobin (an additional criterion of the definition) levels in the general population in developing countries are lower than in the population of developed countries. We aimed to determine the relevance of Truelove and Witts criteria in the Indian population.

Methods

Consecutive patients with acute severe colitis satisfying the Truelove and Witts criteria, hospitalized at a single center between April 2015 and December 2016 were included. All patients received intravenous corticosteroids and 16 required colectomy. The hemoglobin levels at admission were subsequently excluded from the classification criteria, and the effect this had on the criteria for diagnosis was determined.

Results

Out of 61 patients of acute severe colitis diagnosed according to the original Truelove and Witts criteria, 12 patients (20%) had 1 additional criterion, 33 (54%) had 2 additional criteria and 16 (26%) had 3 or more additional criteria in addition to 6 or more blood stained stools on admission. On excluding hemoglobin as an additional criterion from the Truelove and Witts definition, all patients still met the criteria for acute severe colitis.

Conclusions

Truelove and Witts criteria can be used to define acute severe colitis in India, despite lower mean hemoglobin in the native population.

Citations

Citations to this article as recorded by

Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response
Alex Adams, Vipin Gupta, Waled Mohsen, Thomas P Chapman, Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Sudheer Kumar, Saurabh Kedia, Colleen GC McGregor, Tim Ambrose, Bruce D George, Rebecca Palmer, Oliver Brain, Alissa Walsh, Vineet Ahuja, Simon P
Gut.2023; 72(3): 433. CrossRef
Inflammatory bowel disease: An Indian perspective
Mayank Jain, Jayanthi Venkataraman
Indian Journal of Medical Research.2021; 153(4): 421. CrossRef
High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324. CrossRef
Relationship Between Vitamin D Deficiency and Disease Activity in Patients with Inflammatory Bowel Disease in Ahvaz, Iran

Esmat Rasouli, Narges Sadeghi, Abazar Parsi, Seyed Jalal Hashemi, Morteza Nayebi, Aliakbar Shayesteh
Clinical and Experimental Gastroenterology.2020; Volume 13: 419. CrossRef
A current overview of corticosteroid use in active ulcerative colitis
Marco Salice, Fernando Rizzello, Carlo Calabrese, Lucia Calandrini, Paolo Gionchetti
Expert Review of Gastroenterology & Hepatology.2019; 13(6): 557. CrossRef
Optimal management of acute severe ulcerative colitis
Saransh Jain, Vineet Ahuja, Jimmy K Limdi
Postgraduate Medical Journal.2019; 95(1119): 32. CrossRef
A challenge in diagnosis and management of ulcerative colitis in elderly patient with atypical presentation: A reported case
Panutchaya Kongon, Vorapatu Tangsirapat, Vittawat Ohmpornuwat, Kannakrit Sumtong, Vichack Chakrapan Na Ayudhya, Kobkool Chakrapan Na Ayudhya, Paiboon Sookpotarom, Paisarn Vejchapipat
International Journal of Surgery Case Reports.2019; 61: 234. CrossRef

8,164 View
79 Download
6 Web of Science
7 Crossref

IBD

Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease: Paulo Gustavo Kotze, Daniela Oliveira Magro, Barbara Saab, Mansur Paulo Saab, Lilian Vital Pinheiro, Marcia Olandoski, Maria de Lourdes Setsuko Ayrizono, Carlos Augusto Real Martinez, Claudio Saddy Rodrigues Coy; Intest Res 2018;16(1):62-68. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.62

Abstract PDF PubReader ePub

Background/Aims

The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease (CD). This study aimed to identify whether preoperative anti-TNF agents influence the time from diagnosis to surgery.

Methods

An observational retrospective cohort study was conducted on patients with CD submitted to intestinal resections due to complications or medical therapy failure in a period of 7 years. The patients were allocated into 2 groups according to their previous exposure to anti-TNF agents in the preoperative period. Epidemiological aspects regarding age at diagnosis, smoking, perianal disease, and preoperative conventional therapy were considered. A Kaplan-Meier survival analysis was used to outline possible differences between the groups regarding the time to surgery.

Results

A total of 123 patients were included (71 and 52 with and without previous exposure to biologics, respectively). The overall time to surgery was 108±6.9 months (maximum, 276 months). The survival estimation revealed no difference in the mean time to intestinal resection between the groups (99.78±10.62 months in the patients without and 114.01±9.07 months in those with previous anti-TNF use) (log-rank P=0.35). There was no significant difference in the time to surgery regarding perianal CD (P=0.49), smoking (P=0.63), preoperative azathioprine (P=0.073) and steroid use (P=0.58).

Conclusions

The time from diagnosis to surgery was not influenced by the preoperative use of anti-TNF therapy in this cohort of patients.

Citations

Citations to this article as recorded by

Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America
Domingo Balderramo, Abel Botelho Quaresma, Pablo A Olivera, Mariane Christina Savio, Maria Paz Gimenez Villamil, Remo Panaccione, Siew C Ng, Gilaad G Kaplan, Paulo Gustavo Kotze
The Lancet Gastroenterology & Hepatology.2024; 9(3): 263. CrossRef
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intestinal Research.2022; 20(1): 72. CrossRef
Establishing a rabbit model of perianal fistulizing Crohn’s disease
Shuang-Shuang Lu, Wen-Jia Liu, Qiu-Ya Niu, Chun-Yan Huo, Yu-Qing Cheng, En-Jing Wang, Rong-Nan Li, Fang-Fang Feng, Yi-Ming Cheng, Rong Liu, Jin Huang
World Journal of Gastroenterology.2022; 28(15): 1536. CrossRef
Modern surgical strategies for perianal Crohn's disease
Gilmara Pandolfo Zabot, Ornella Cassol, Rogerio Saad-Hossne, Willem Bemelman
World Journal of Gastroenterology.2020; 26(42): 6572. CrossRef
Increased prevalence of anti‐TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood
James J. Ashton, Florina Borca, Enrico Mossotto, Tracy Coelho, Akshay Batra, Nadeem A. Afzal, Hang T. T. Phan, Michael Stanton, Sarah Ennis, Robert Mark Beattie
Alimentary Pharmacology & Therapeutics.2019; 49(4): 398. CrossRef
Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn’s Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study
Roy Frei, Nicolas Fournier, Jonas Zeitz, Michael Scharl, Bernhard Morell, Thomas Greuter, Philipp Schreiner, Benjamin Misselwitz, Ekaterina Safroneeva, Alain M Schoepfer, Stephan R Vavricka, Gerhard Rogler, Luc Biedermann
Journal of Crohn's and Colitis.2019; 13(10): 1292. CrossRef
Are Surgical Rates Decreasing in the Biological Era In IBD?
Francesca Di Candido, Gionata Fiorino, Marco Spadaccini, Silvio Danese, Antonino Spinelli
Current Drug Targets.2019; 20(13): 1356. CrossRef

5,386 View
57 Download
8 Web of Science
7 Crossref

IBD

Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis: Vikram Narang, Ravneet Kaur, Bhavna Garg, Ramit Mahajan, Vandana Midha, Neena Sood, Ajit Sood; Intest Res 2018;16(1):55-61. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.55

Abstract PDF PubReader ePub

Background/Aims

The therapeutic goal for treating ulcerative colitis (UC) patients has shifted to achieving mucosal healing over the past few years. However, at present, limited data is available on the correlation between endoscopic findings and histological remission in patients with endoscopic mucosal healing.

Methods

This was a prospective observational study conducted over a period of 18 months (January 2014 to June 2015) at Dayanand Medical College and Hospital, Ludhiana, Punjab, India. Patients diagnosed with UC who had been in clinical remission (n=76) for at least 6 months were evaluated for endoscopic remission. Those in endoscopic remission (Mayo score ≤1; 46/76, 60.5%) were subjected to multiple biopsies from the rectosigmoid region and histological remission, which was then defined as grade 0/1 as per the Geboes criteria.

Results

Of the 46 patients in endoscopic remission (age, 18–73 years; male:female=1.5:1.0), majority had E1 (proctitis) disease (21/46, 45.6%) followed by E2 (left sided colitis) (18/46, 39.1%) and E3 disease (pancolitis) (7/46, 15.2%) at baseline. Histological remission was noted in 67.3% (31/46) of the patients, while 32.7% (15/46) still retained the histologically active disease in the form of infiltration of the lamina propria by eosinophils and neutrophils (13/15, 86.6%), cryptitis (14/15, 93.3%), and crypt abscesses (8/15, 53.3%). On follow-up, after 1 year, 87.1% (27/31) of the patients who had been in histological remission remained clinically asymptomatic, while 12.9% (4/31) had relapsed. Among the 15 histologically active patients, 46.6% (7/15) remained in clinical remission, while 53.3% (8/15) had relapsed.

Conclusions

Histological remission, rather than endoscopic remission, predicts a sustained clinical remission and allows monitoring of therapy for the subsequent disease course in patients with UC.

Citations

Citations to this article as recorded by

Advanced Endoscopic Imaging for Assessing Mucosal Healing and Histologic Remission in Inflammatory Bowel Diseases
Tommaso Pessarelli, Gian Eugenio Tontini, Helmut Neumann
Gastrointestinal Endoscopy Clinics of North America.2025; 35(1): 159. CrossRef
Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis
Michael Youssef, Kelly Dong, So Jeong Lee, Neeraj Narula
Inflammatory Bowel Diseases.2024; 30(1): 125. CrossRef
Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Mohammad Shehab, Sahad Al Akram, Amro Hassan, Fatema Alrashed, Vipul Jairath, Talat Bessissow
Inflammatory Bowel Diseases.2024; 30(4): 563. CrossRef
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus
Ferdinando D’Amico, Fernando Magro, Britta Siegmund, Taku Kobayashi, Paulo Gustavo Kotze, Virginia Solitano, Benedicte Caron, Sameer Al Awadhi, Ailsa Hart, Vipul Jairath, Axel Dignass, Laurent Peyrin-Biroulet, Silvio Danese
Inflammatory Bowel Diseases.2024; 30(6): 1009. CrossRef
Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib
Sara van Gennep, Ivan C N Fung, Djuna C de Jong, Rishand K Ramkisoen, Esmé Clasquin, Jitteke de Jong, Leonie C S de Vries, Wouter J de Jonge, Krisztina B Gecse, Mark Löwenberg, John C Woolcott, Aart Mookhoek, Geert R D’Haens
Journal of Crohn's and Colitis.2024; 18(8): 1283. CrossRef
Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta‐analysis of randomized controlled trials
Othman Saleh, Mohamed T. Abuelazm, Islam Mohamed, Alaa Ramadan, Mohammad Assaf, Ahmad Alzoubi, Majd M. AlBarakat, Basel Abdelazeem
JGH Open.2024;[Epub] CrossRef
Adequacy of sigmoidoscopy as compared to colonoscopy for assessment of disease activity in patients of ulcerative colitis: a prospective study
Sameet Tariq Patel, Anuraag Jena, Sanjay Chandnani, Shubham Jain, Pankaj Nawghare, Saurabh Bansal, Harsh Gandhi, Rishikesh Malokar, Jay Chudasama, Prasanta Debnath, Seemily Kahmei, Rima Kamat, Sangeeta Kini, Qais Q Contractor, Pravin M Rathi
Intestinal Research.2024; 22(3): 310. CrossRef
Deep mucosal healing in ulcerative colitis: how deep is better?
Xin Jin, Yan You, Gechong Ruan, Weixun Zhou, Ji Li, Jingnan Li
Frontiers in Medicine.2024;[Epub] CrossRef
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis
Ji Eun Kim, Minjee Kim, Min-Ji Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Sang Yun Ha, Young-Ho Kim
Scientific Reports.2024;[Epub] CrossRef
Epithelial neutrophil localization and tight junction Claudin‐2 expression are innovative outcome predictors in inflammatory bowel disease
Irene Zammarchi, Giovanni Santacroce, Miguel Puga‐Tejada, Brian Hayes, Rory Crotty, Elaine O’Driscoll, Snehali Majumder, Wiktoria Kaczmarczyk, Yasuharu Maeda, Jane McCarthy, Kathleen Sugrue, Caitriona O’Sullivan, Louise Burke, Subrata Ghosh, Marietta Iacu
United European Gastroenterology Journal.2024;[Epub] CrossRef
Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1
Gyeol Seong, Joo Hye Song, Ji Eun Kim, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Seok-Hyung Kim, Sang Yun Ha, Young-Ho Kim
Inflammatory Bowel Diseases.2023; 29(2): 238. CrossRef
(Re)Appraising Remission in Ulcerative Colitis
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Charles N Bernstein, David T Rubin
Inflammatory Bowel Diseases.2023; 29(8): 1317. CrossRef
Artificial Intelligence Enables Quantitative Assessment of Ulcerative Colitis Histology
Fedaa Najdawi, Kathleen Sucipto, Pratik Mistry, Stephanie Hennek, Christina K.B. Jayson, Mary Lin, Darren Fahy, Shawn Kinsey, Ilan Wapinski, Andrew H. Beck, Murray B. Resnick, Archit Khosla, Michael G. Drage
Modern Pathology.2023; 36(6): 100124. CrossRef
Impaired Intestinal Permeability Assessed by Confocal Laser Endomicroscopy—A New Potential Therapeutic Target in Inflammatory Bowel Disease
Stefan Chiriac, Catalin Victor Sfarti, Horia Minea, Carol Stanciu, Camelia Cojocariu, Ana-Maria Singeap, Irina Girleanu, Tudor Cuciureanu, Oana Petrea, Laura Huiban, Cristina Maria Muzica, Sebastian Zenovia, Robert Nastasa, Remus Stafie, Adrian Rotaru, Er
Diagnostics.2023; 13(7): 1230. CrossRef
HISTOPATHOLOGICAL FEATURES IN RELAPSE OF ULCERATIVE COLITIS.
Saroash Iqbal, Aman Ur Rehman, Nausheen Henna, Zara Madiha, Sahar Moeed, Uzma Aslam
JAIMC: Journal of Allama Iqbal Medical College.2023;[Epub] CrossRef
Mucosal Atrophy Predicts Poorer Outcomes in Pediatric Ulcerative Colitis—A National Inception Cohort Study
Emily Stenke, Lorraine Stallard, Sarah Cooper, Anna Dominik, Abigail Pilkington, Sheila Sugrue, Maureen O’Sullivan, Michael McDermott, Shoana Quinn, Annemarie Broderick, Billy Bourke, Séamus Hussey
Journal of Pediatric Gastroenterology & Nutrition.2023; 76(5): 603. CrossRef
Automating Ground Truth Annotations for Gland Segmentation Through Immunohistochemistry
Tushar Kataria, Saradha Rajamani, Abdul Bari Ayubi, Mary Bronner, Jolanta Jedrzkiewicz, Beatrice S. Knudsen, Shireen Y. Elhabian
Modern Pathology.2023; 36(12): 100331. CrossRef
Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing
Alina Ecaterina Jucan, Otilia Gavrilescu, Mihaela Dranga, Iolanda Valentina Popa, Ioana-Ruxandra Mihai, Vasile-Claudiu Mihai, Gabriela Stefanescu, Vasile Liviu Drug, Cristina Cijevschi Prelipcean, Radu-Alexandru Vulpoi, Oana-Bogdana Barboi, Irina Ciortesc
Biomedicines.2023; 11(11): 3090. CrossRef
Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease
Barbara Sosna, David Aebisher, Angelika Myśliwiec, Klaudia Dynarowicz, Dorota Bartusik-Aebisher, Piotr Oleś, Grzegorz Cieślar, Aleksandra Kawczyk-Krupka
International Journal of Molecular Sciences.2023; 25(1): 202. CrossRef
Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis
Niels Vande Casteele, Jonathan A Leighton, Shabana F Pasha, Frank Cusimano, Aart Mookhoek, Catherine E Hagen, Christophe Rosty, Reetesh K Pai, Rish K Pai
Inflammatory Bowel Diseases.2022; 28(4): 539. CrossRef
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis
Silvio Danese, Barrett G. Levesque, Brian G. Feagan, Alina Jucov, Bal Raj Bhandari, Rish K. Pai, Kristen Taylor Meadows, Brian J. Kirby, Jean‐Marie Bruey, Allan Olson, Robin Osterhout, Courtney Van Biene, Julia Ford, Richard Aranda, Kartik Raghupathi, Wil
Alimentary Pharmacology & Therapeutics.2022; 55(4): 401. CrossRef
PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system
Xianyong Gui, Alina Bazarova, Rocìo del Amor, Michael Vieth, Gert de Hertogh, Vincenzo Villanacci, Davide Zardo, Tommaso Lorenzo Parigi, Elin Synnøve Røyset, Uday N Shivaji, Melissa Anna Teresa Monica, Giulio Mandelli, Pradeep Bhandari, Silvio Danese, Jos
Gut.2022; 71(5): 889. CrossRef
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis
Angelo Viscido, Marco Valvano, Gianpiero Stefanelli, Annalisa Capannolo, Chiara Castellini, Eugenia Onori, Antonio Ciccone, Filippo Vernia, Giovanni Latella
BMC Gastroenterology.2022;[Epub] CrossRef
Appendiceal Orifice Inflammation Is Associated with Lower Rate of Complete Endoscopic Remission in Patients with Ulcerative Colitis
Chang Kyo Oh, Han Hee Lee, Jin Su Kim, Bo-In Lee, Young-Seok Cho
Journal of Personalized Medicine.2022; 12(5): 748. CrossRef
ECCO Position on Harmonisation of Crohn’s Disease Mucosal Histopathology
F Magro, J Sabino, F Rosini, M Tripathi, P Borralho, P Baldin, S Danese, A Driessen, I O Gordon, M Iacucci, N Noor, M Svrcek, L Peyrin-Biroulet, R Feakins
Journal of Crohn's and Colitis.2022; 16(6): 876. CrossRef
Constrained multiple instance learning for ulcerative colitis prediction using histological images
Rocío del Amor, Pablo Meseguer, Tommaso Lorenzo Parigi, Vincenzo Villanacci, Adrián Colomer, Laëtitia Launet, Alina Bazarova, Gian Eugenio Tontini, Raf Bisschops, Gert de Hertogh, Jose G. Ferraz, Martin Götz, Xianyong Gui, Bu’Hussain Hayee, Mark Lazarev,
Computer Methods and Programs in Biomedicine.2022; 224: 107012. CrossRef
Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
Ferdinando D’Amico, Gionata Fiorino, Virginia Solitano, Eugenia Massarini, Lucas Guillo, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Stefanos Bonovas, Fernando Magro, Laurent Peyrin‐Biroulet, Silvio Danese
United European Gastroenterology Journal.2022; 10(7): 775. CrossRef
Efficacy and safety of ozanimod for ulcerative colitis (review)
M. V. Shapina, A. V. Poletova, T. A. Baranova
Koloproktologia.2022; 21(3): 119. CrossRef
Deep learning-based automated quantification of goblet cell mucus using histological images as a predictor of clinical relapse of ulcerative colitis with endoscopic remission
Jun Ohara, Tetsuo Nemoto, Yasuharu Maeda, Noriyuki Ogata, Shin-ei Kudo, Toshiko Yamochi
Journal of Gastroenterology.2022; 57(12): 962. CrossRef
Clinical Predictors of Response to Faecal Microbiota Transplantation in Patients with Active Ulcerative Colitis
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Kirandeep Kaur, Dharmatma Singh, Namita Bansal, Khushdeep Dharni
Journal of Crohn's and Colitis.2021; 15(2): 238. CrossRef
Therapeutic drug monitoring of anti‐tumour necrosis factor‐α agents in inflammatory bowel disease: Limits and improvements
José María Giráldez‐Montero, Jaime Gonzalez‐Lopez, Manuel Campos‐Toimil, María Jesús Lamas‐Díaz
British Journal of Clinical Pharmacology.2021; 87(5): 2216. CrossRef
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Fernando Magro, Catarina Alves, Joanne Lopes, Susana Lopes, Helena Tavares de Sousa, José Cotter, Vitor Macedo da Silva, Paula Lago, Ana Vieira, Mariana Brito, Maria A.M. Duarte, Francisco Portela, João P. Silva, Paula Ministro, Bruno Arroja, Liliana Carv
Clinical Gastroenterology and Hepatology.2021; 19(12): 2567. CrossRef
Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Akshita Gupta, Amy Yu, Laurent Peyrin-Biroulet, Ashwin N. Ananthakrishnan
Clinical Gastroenterology and Hepatology.2021; 19(9): 1800. CrossRef
Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis
Ludimilla dos Reis Malvão, Kalil Madi, Barbara Cathalá Esberard, Renata Fernandes de Amorim, Kelly dos Santos Silva, Katia Farias e Silva, Heitor Siffert Pereira de Souza, Ana Teresa Pugas Carvalho
Medicine.2021; 100(3): e24058. CrossRef
Real-life evaluation of histologic scores for Ulcerative Colitis in remission
Christian Børde Arkteg, Sveinung Wergeland Sørbye, Lene Buhl Riis, Stig Manfred Dalen, Jon Florholmen, Rasmus Goll, Valérie Pittet
PLOS ONE.2021; 16(3): e0248224. CrossRef
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
William J Sandborn, Brian G Feagan, Stephen Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C Wolf, Geert D’Haens
Journal of Crohn's and Colitis.2021; 15(7): 1120. CrossRef
Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission
Marietta Iacucci, Louisa Jeffery, Animesh Acharjee, Olga Maria Nardone, Davide Zardo, Samuel C L Smith, Alina Bazarova, Rosanna Cannatelli, Uday N Shivaji, John Williams, Georgios Gkoutos, Subrata Ghosh
Inflammatory Bowel Diseases.2021; 27(11): 1719. CrossRef
Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease
Samuel C. L. Smith, Carl Banbury, Davide Zardo, Rosanna Cannatelli, Olga M. Nardone, Uday N. Shivaji, Subrata Ghosh, Pola Goldberg Oppenheimer, Marietta Iacucci, Pradeep Dudeja
PLOS ONE.2021; 16(6): e0252210. CrossRef
Accurate diagnosis of endoscopic mucosal healing in ulcerative colitis using deep learning and machine learning
Tien-Yu Huang, Shan-Quan Zhan, Peng-Jen Chen, Chih-Wei Yang, Henry Horng-Shing Lu
Journal of the Chinese Medical Association.2021; 84(7): 678. CrossRef
Is histological remission of ulcerative colitis achievable?
Oleg V. Knyazev, Anna V. Kagramanova, Sergei G. Khomeriki, Asfold I. Parfenov
Terapevticheskii arkhiv.2021; 93(8): 975. CrossRef
Current Trends in IBD—Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System
Yunki Y Yau, Valerie C Wasinger, Robert P Hirten, Emil Chuang, Merodean Huntsman, Jack Stylli, Jeff Shimizu, Vijay Yajnik, Jeffrey Smith, Shaoying N Lee, Sharat Singh, Christopher Wahl, Rupert W Leong, Bruce E Sands
Inflammatory Bowel Diseases.2021; 27(Supplement): S17. CrossRef
Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
Oleg V. Knyazev, Sergey G. Khomeriki, Аnna V. Kagramanova, Albina A. Lishchinskaya, Olga A. Smirnova, Karina K. Noskova, Asfold I. Parfenov
Terapevticheskii arkhiv.2021; 93(12): 1435. CrossRef
Histologic Activity and Steroid Use History are Risk Factors of Clinical Relapse in Ulcerative Colitis with Endoscopic Remission
Gyeol Seong, Joo Hye Song, Ji Eun Kim, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Seok-Hyung Kim, Sang Yun Ha, Young-Ho Kim
SSRN Electronic Journal .2021;[Epub] CrossRef
Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study
Jimil Shah, Usha Dutta, Ashim Das, Vishal Sharma, Harshal Mandavdhare, Pankaj Sharma, Dimple Kalsi, Priyanka Popli, Rakesh Kochhar
JGH Open.2020; 4(3): 382. CrossRef
Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis
Rish K. Pai, Douglas J. Hartman, Claudia Ramos Rivers, Miguel Regueiro, Marc Schwartz, David G. Binion, Reetesh K. Pai
Clinical Gastroenterology and Hepatology.2020; 18(11): 2510. CrossRef
Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
Natsuki Ishida, Takahiro Miyazu, Ryosuke Takano, Satoshi Tamura, Shinya Tani, Takuma Kagami, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroaki Miyajima, Ken Sugimoto
BMC Gastroenterology.2020;[Epub] CrossRef
ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology
Fernando Magro, Glen Doherty, Laurent Peyrin-Biroulet, Magali Svrcek, Paula Borralho, Alissa Walsh, Fatima Carneiro, Francesca Rosini, Gert de Hertogh, Luc Biedermann, Lieven Pouillon, Michael Scharl, Monika Tripathi, Silvio Danese, Vincenzo Villanacci, R
Journal of Crohn's and Colitis.2020; 14(11): 1503. CrossRef
Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment
Lorenzo Bertani, Maria Gloria Mumolo, Gherardo Tapete, Eleonora Albano, Giovanni Baiano Svizzero, Federico Zanzi, Linda Ceccarelli, Massimo Bellini, Santino Marchi, Francesco Costa
European Journal of Gastroenterology & Hepatology.2020; 32(9): 1091. CrossRef
What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?
Jongbeom Shin, Sung Min Kong, Gyeol Seong, Young-Ho Kim
International Journal of Colorectal Disease.2020; 35(12): 2249. CrossRef
Treat to target or ‘treat to clear’ in inflammatory bowel diseases: one step further?
Arianna Dal Buono, Giulia Roda, Marjorie Argollo, Eirini Zacharopoulou, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Gastroenterology & Hepatology.2020; 14(9): 807. CrossRef
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis
Hyuk Yoon, Sushrut Jangi, Parambir S. Dulai, Brigid S. Boland, Larry J. Prokop, Vipul Jairath, Brian G. Feagan, William J. Sandborn, Siddharth Singh
Gastroenterology.2020; 159(4): 1262. CrossRef
Assessing Severity of Disease in Patients with Ulcerative Colitis
Baldeep Singh Pabla, David Allen Schwartz
Gastroenterology Clinics of North America.2020; 49(4): 671. CrossRef
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
Intestinal Research.2020; 18(4): 355. CrossRef
‘Treat to Target’ in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy
Arianna Dal Buono, Giulia Roda, Marjorie Argollo, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Current Drug Targets.2020; 22(1): 117. CrossRef
What is the role of histopathology in the evaluation of disease activity in Crohn’s Disease?
Rish K. Pai, Vipul Jairath
Best Practice & Research Clinical Gastroenterology.2019;[Epub] CrossRef
Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis
Lieven Pouillon, Hélène Rousseau, Hélène Busby-Venner, Marcelo De Carvalho Bittencourt, Myriam Choukour, Guillaume Gauchotte, Camille Zallot, Silvio Danese, Cédric Baumann, Laurent Peyrin-Biroulet
Journal of Crohn's and Colitis.2019; 13(8): 970. CrossRef
Prediction of treatment outcome and relapse in inflammatory bowel disease
Jun Kato, Takeichi Yoshida, Sakiko Hiraoka
Expert Review of Clinical Immunology.2019; 15(6): 667. CrossRef
Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study
Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta, Vikram Narang, Tarundeep Singh, Anmol Singh Pannu
Journal of Crohn's and Colitis.2019; 13(10): 1311. CrossRef
Mucosal healing in inflammatory bowel disease: Expanding horizon
Jimil Shah, Manik Lal Thakur, Usha Dutta
Indian Journal of Gastroenterology.2019; 38(2): 98. CrossRef
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
Ryan Ungaro, Jean-Frédéric Colombel, Trevor Lissoos, Laurent Peyrin-Biroulet
American Journal of Gastroenterology.2019; 114(6): 874. CrossRef
A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials
Katherine Li, Richard Strauss, Colleen Marano, Linda E Greenbaum, Joshua R Friedman, Laurent Peyrin-Biroulet, Carrie Brodmerkel, Gert De Hertogh
Journal of Crohn's and Colitis.2019; 13(8): 1025. CrossRef
Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?
Olga Maria Nardone, Rosanna Cannatelli, Davide Zardo, Subrata Ghosh, Iacucci Marietta
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef
The emerging role of histologic disease activity assessment in ulcerative colitis
Rish K. Pai, Vipul Jairath, Niels Vande Casteele, Florian Rieder, Claire E. Parker, Gregory Y. Lauwers
Gastrointestinal Endoscopy.2018; 88(6): 887. CrossRef
Temporal clinical, proteomic, histological and cellular immune responses of dextran sulfate sodium-induced acute colitis
Natalia Schneider Nunes, Saejeong Kim, Maggie Sundby, Parwathy Chandran, Scott Robert Burks, Ana Helena Paz, Joseph Alan Frank
World Journal of Gastroenterology.2018; 24(38): 4341. CrossRef
Can histologic remission be a better prognostic factor and therapeutic target beyond endoscopic mucosal healing in patients with ulcerative colitis?
Hyo Jun Ahn, Sang-Bum Kang
Intestinal Research.2018; 16(1): 1. CrossRef

7,318 View
131 Download
64 Web of Science
65 Crossref

Predictive factors for malignancy in undiagnosed isolated small bowel strictures: Ujjwal Sonika, Sujeet Saha, Saurabh Kedia, Nihar Ranjan Dash, Sujoy Pal, Prasenjit Das, Vineet Ahuja, Peush Sahni; Intest Res 2017;15(4):518-523. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.518

Abstract PDF PubReader ePub

Background/Aims

Patients with small bowel strictures have varied etiologies, including malignancy. Little data are available on the demographic profiles and etiologies of small bowel strictures in patients who undergo surgery because of intestinal obstruction but do not have a definitive pre-operative diagnosis.

Methods

Retrospective data were analyzed for all patients operated between January 2000 and October 2014 for small bowel strictures without mass lesions and a definite diagnosis after imaging and endoscopic examinations. Demographic parameters, imaging, endoscopic, and histological data were extracted from the medical records. Univariate and multivariate analyses were conducted to identify factors that could differentiate between intestinal tuberculosis (ITB) and Crohn's disease (CD) and between malignant and benign strictures.

Results

Of the 7,425 reviewed medical records, 89 met the inclusion criteria. The most common site of strictures was the proximal small intestine (41.5%). The most common histological diagnoses in patients with small bowel strictures were ITB (26.9%), CD (23.5%), non-specific strictures (20.2%), malignancy (15.5%), ischemia (10.1%), and other complications (3.4%). Patients with malignant strictures were older than patients with benign etiologies (47.6±15.9 years vs. 37.4±16.4 years, P=0.03) and age >50 years had a specificity for malignant etiology of 80%. Only 7.1% of the patients with malignant strictures had more than 1 stricture and 64% had proximally located strictures. Diarrhea was the only factor that predicted the diagnosis of CD 6.5 (95% confidence interval, 1.10–38.25; P=0.038) compared with the diagnosis of ITB.

Conclusions

Malignancy was the cause of small bowel strictures in approximately 16% patients, especially among older patients with a single stricture in the proximal location. Empirical therapy should be avoided and the threshold for surgical resection is low in these patients.

Citations

Citations to this article as recorded by

Cryptogenic multifocal ulcerous stenosing enteritis: A ray of light on the umbra of the dark continent
Mithu Bhowmick, Vishal Sharma
Indian Journal of Gastroenterology.2024; 43(6): 1082. CrossRef
Ileal endometriosis: a rare cause of multifocal small bowel strictures
Timothy Peacock, William Harrison, Alexandra Limmer, Suzanne Di Sano, King‐Sang Wong
ANZ Journal of Surgery.2022; 92(7-8): 1914. CrossRef
Infectious diseases affecting the small bowel – what not to miss
Martin Keuchel, Marc Bota, Peter Baltes
Current Opinion in Gastroenterology.2021; 37(3): 255. CrossRef
Small bowel ulcers
Martin Keuchel, Niehls Kurniawan, Peter Baltes
Current Opinion in Gastroenterology.2019; 35(3): 213. CrossRef
Rebleeding rate and risk factors in nonsteroidal anti‐inflammatory drug‐induced enteropathy
Junseok Park, Seong Ran Jeon, Jin‐Oh Kim, Hyun Gun Kim, Tae Hee Lee, Jun‐Hyung Cho, Bong Min Ko, Joon Seong Lee, Moon Sung Lee
Journal of Digestive Diseases.2018; 19(5): 279. CrossRef

5,188 View
59 Download
5 Web of Science
5 Crossref

High C-reactive protein level is associated with high-risk adenoma: Hyae Min Lee, Jae Myung Cha, Jung Lok Lee, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Jin Young Yoon, Joung Il Lee; Intest Res 2017;15(4):511-517. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.511

Abstract PDF PubReader ePub

Background/Aims

There is substantial evidence supporting a role of inflammation in the pathogenesis of colorectal cancer; however, little is known about the association between serum C-reactive protein (CRP) and the risk of colorectal adenoma. This study was conducted to investigate the association between serum CRP and colorectal adenoma risk.

Methods

A retrospective cross-sectional study was performed on first-time screening colonoscopies in asymptomatic subjects who also had their serum CRP level measured during a routine health check-up between September 2006 and September 2009 in Korea. Serum CRP level was compared between high-risk and low-risk adenoma groups and independent predictors of high-risk adenoma were analyzed using multivariate regression analysis.

Results

Among the 3,309 eligible patients, the high-risk adenoma group had higher serum CRP levels than the low-risk adenoma group (P=0.000). In addition, patients with a high-risk adenoma were more frequently included in the high CRP group than in the low CRP group (8.6% vs. 4.0%, P<0.001). The prevalence of high-risk adenoma was 3.5 times higher in the highest quartile of CRP level (P=0.000) compared with that in the lowest quartile. In logistic regression analysis, a higher quartile CRP level was found to be an independent risk factor for high-risk adenoma (odds ratio, 1.8; 95% confidence interval, 1.3–2.5; P=0.000).

Conclusions

High CRP level is associated with high-risk adenoma in both men and women. Our data may support the association between chronic inflammation and colorectal neoplasia, which warrants further investigation.

Citations

Citations to this article as recorded by

Short-term and residential exposure to air pollution: Associations with inflammatory biomarker levels in adults living in northern France
Marion Darras-Hostens, Djamal Achour, Manon Muntaner, Céline Grare, Gianni Zarcone, Guillaume Garçon, Philippe Amouyel, Farid Zerimech, Régis Matran, Jean-Marc Lo Guidice, Luc Dauchet
Science of The Total Environment.2022; 833: 154985. CrossRef
Functional Plasmon-Activated Water Increases Akkermansia muciniphila Abundance in Gut Microbiota to Ameliorate Inflammatory Bowel Disease
Chun-Chao Chang, Chih-Yi Liu, I-Chia Su, Yuarn-Jang Lee, Hsing-Jung Yeh, Wen-Chao Chen, Chih-Jui Yu, Wei-Yu Kao, Yu-Chuan Liu, Chi-Jung Huang
International Journal of Molecular Sciences.2022; 23(19): 11422. CrossRef
Self-reported Metabolic Risk Factor Associations with Adenomatous, Sessile Serrated, and Synchronous Adenomatous and Sessile Serrated Polyps
Celina N. Santiago, Samara Rifkin, Julia Drewes, Gerard Mullin, Emma Spence, Linda M. Hylind, Joell J. Gills, David Kafonek, David M. Cromwell, Louis La Luna, Francis Giardello, Cynthia L. Sears
Cancer Prevention Research.2021; 14(7): 697. CrossRef
Single‐incision laparoscopic colectomy for ascending colon tumor with relapsing polychondritis
Ryugo Teranishi, Norikatsu Miyoshi, Kansuke Kido, Masayuki Nishide, Shiki Fujino, Takayuki Ogino, Hidekazu Takahashi, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizusima, Masaki Mori, Yuichiro Doki
Asian Journal of Endoscopic Surgery.2020; 13(4): 569. CrossRef
Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin
Miren Alustiza, Eva Hernández-Illán, Miriam Juárez, Mar Giner-Calabuig, Cristina Mira, Alejandro Martínez-Roca, Luis Bujanda, Francisco Rodríguez-Moranta, Joaquín Cubiella, Luisa de-Castro, José-Carlos Marín-Gabriel, Alberto Herreros-de-Tejada, Fernando F
Clinical and Translational Gastroenterology.2020; 11(3): e00143. CrossRef

6,338 View
56 Download
5 Web of Science
5 Crossref

Local recurrence and subsequent endoscopic treatment after endoscopic piecemeal mucosal resection with or without precutting in the colorectum: Myeongsook Seo, Eun Mi Song, Gwang Un Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon; Intest Res 2017;15(4):502-510. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.502

Abstract PDF PubReader ePub

Background/Aims

Precutting before endoscopic piecemeal mucosal resection (EPMR) may increase colorectal polyp resection effectiveness. We aimed to identify risk factors for recurrence after conventional EPMR (CEPMR) and precut EPMR (PEPMR) and investigated endoscopic treatment outcomes for recurrent cases.

Methods

The medical records of patients with colorectal polyps treated by EPMR were analyzed. Patients without follow-up surveillance colonoscopies were excluded.

Results

Among 359 lesions, the local recurrence rate on the first surveillance colonoscopy was 5.8% (18/312) and 6.4% (3/47) after CEPMR and PEPMR, respectively. Among lesions without recurrence at the first surveillance colonoscopy, the rates of late recurrence on subsequent surveillance colonoscopy were 3.9% (6/152) and 0% after CEPMR and PEPMR, respectively. Larger tumor size was the only independent risk factor for recurrence (odds ratio, 7.93; 95% confidence interval, 1.95–32.30; P<0.001). Endoscopic treatment was performed for all 27 recurrences. A combination of ≥2 endoscopic treatment modalities was used in 19 of 27 recurrences (70.4%). Surveillance colonoscopies were performed in 20 of 27 recurrences after endoscopic treatment. One (5.0%) had a re-recurrence and was treated by surgical resection because recurrence occurred at the appendiceal orifice. Nineteen of 20 lesions (95.0%) could be cured endoscopically, although 3 of the 19 showed second or third recurrences and were treated by repeat endoscopic resection.

Conclusions

The local recurrence rates after CEPMR and PEPMR were similar. Larger tumor size was an independent risk factor for local recurrence after EPMR. Endoscopic treatment of recurrences resulted in high cure rates, although combination methods were necessary in many cases.

Citations

Citations to this article as recorded by

Cold Versus Hot Endoscopic Mucosal Resection for Sessile Serrated Colorectal Polyps ≥10 mm
Talia F. Malik, Babu P. Mohan, Smit Deliwala, Lena L. Kassab, Saurabh Chandan, Neil R. Sharma, Douglas G. Adler
Journal of Clinical Gastroenterology.2024; 58(9): 889. CrossRef
Cold EMR vs. Hot EMR for the removal of sessile serrated polyps larger than 10 mm: a systematic review and meta-analysis
Cong Ding, Jian-feng Yang, Xia Wang, Yi-feng Zhou, Hayat Khizar, Zheng Jin, Xiao-feng Zhang
BMC Surgery.2024;[Epub] CrossRef
Does precutting prior to endoscopic piecemeal resection of large colorectal neoplasias reduce local recurrence? A KASID multicenter study
Hong Jin Yoon, Dae Kyung Sohn, Yunho Jung, Hyun Seok Lee, Hoon Sup Koo, Kyeong Ok Kim, Jeong Eun Shin, Hyun Gun Kim, Il Kwun Chung, Young Hwangbo
Surgical Endoscopy.2022; 36(5): 3433. CrossRef
Adenoma Recurrence after Endoscopic Piecemeal Mucosal Resection of Colorectal Flat Lesions: Applicability of the Sydney EMR Recurrence Tool in a Non-Tertiary Centre
Maria Azevedo Silva, Carina Leal, André Ruge, Alexandra Fernandes, Liliana Eliseu, Helena Vasconcelos
GE - Portuguese Journal of Gastroenterology.2022; 29(4): 247. CrossRef
Management of the malignant colorectal polyp
Matthew Symer, James Connolly, Heather Yeo
Current Problems in Surgery.2022; 59(5): 101124. CrossRef
Risk factors for local recurrence of large gastrointestinal lesions after endoscopic mucosal resection
Yasar Colak, Badar Hasan, Walid Hassaballa, Mamoon Ur Rashid, Victor Strassmann, Giovanna DaSilva, Steven D. Wexner, Tolga Erim
Techniques in Coloproctology.2022; 26(7): 545. CrossRef
Cost of Endoscopic Submucosal Dissection Versus Endoscopic Piecemeal Mucosal Resection in the Colorectum
Nam Seok Ham, Jeongseok Kim, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Digestive Diseases and Sciences.2020; 65(4): 969. CrossRef
Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
Intestinal Research.2020; 18(1): 96. CrossRef
Efficacy and Safety of Endoscopic Resection of Sessile Serrated Polyps 10 mm or Larger: A Systematic Review and Meta-Analysis
Viveksandeep Thoguluva Chandrasekar, Muhammad Aziz, Harsh K. Patel, Naaz Sidhu, Abhiram Duvvuri, ChandraShekhar Dasari, Kevin F. Kennedy, Ashwini Ashwath, Marco Spadaccini, Madhav Desai, Ramprasad Jegadeesan, Anjana Sathyamurthy, Prashanth Vennalaganti, D
Clinical Gastroenterology and Hepatology.2020; 18(11): 2448. CrossRef
Cold snare piecemeal EMR of large sessile colonic polyps ≥20 mm (with video)
Dileep Mangira, Karla Cameron, Koen Simons, Simon Zanati, Richard LaNauze, Spiro Raftopoulos, Gregor Brown, Alan Moss
Gastrointestinal Endoscopy.2020; 91(6): 1343. CrossRef

6,473 View
82 Download
10 Web of Science
10 Crossref

Is methylation analysis of SFRP2, TFPI2, NDRG4, and BMP3 promoters suitable for colorectal cancer screening in the Korean population?: Soo-Kyung Park, Hae Lim Baek, Junghee Yu, Ji Yeon Kim, Hyo-Joon Yang, Yoon Suk Jung, Kyu Yong Choi, Hungdai Kim, Hyung Ook Kim, Kyung Uk Jeong, Ho-Kyung Chun, Kyungeun Kim, Dong Il Park; Intest Res 2017;15(4):495-501. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.495

Abstract PDF PubReader ePub

Background/Aims

Colorectal cancer (CRC) screening using stool DNA was recently found to yield good detection rates. A multi-target stool DNA test (Cologuard®, Exact Sciences), including methylated genes has been recently approved by the U.S. Food and Drug Administration. The aim of this study was to validate these aberrantly methylated genes as stool-based DNA markers for detecting CRC and colorectal advanced adenoma (AA) in the Korean population.

Methods

A single-center study was conducted in 36 patients with AA; 35 patients with CRC; and 40 endoscopically diagnosed healthy controls using CRC screening colonoscopy. The methylation status of the SFRP2, TFPI2, NDRG4, and BMP3 promoters was investigated blindly using bisulfate-modified stool DNA obtained from 111 participants. Methylation status was investigated by methylation-specific polymerase chain reaction.

Results

Methylated SFRP2, TFPI2, NDRG4, and BMP3 promoters were detected in 60.0%, 31.4%, 68.8%, and 40.0% of CRC samples and in 27.8%, 27.8%, 27.8%, and 33.3% of AA samples, respectively. The sensitivities obtained using 4 markers to detect CRC and AA were 94.3% and 72.2%, respectively. The specificity was 55.0%.

Conclusions

Our results demonstrate that the SFRP2, TFPI2, NDRG4, and BMP3 promoter methylation analysis of stool sample DNA showed high sensitivity but low specificity for detecting CRC and AA. Because of the low specificity, 4 methylated markers might not be sufficient for CRC screening in the Korean population. Further large-scale studies are required to validate the methylation of these markers in the Asian population and to find new markers for the Asian population.

Citations

Citations to this article as recorded by

DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine
Jingxin Ye, Jianfeng Zhang, Weifeng Ding
Exploration of Targeted Anti-tumor Therapy.2024; 5(1): 34. CrossRef
Pathogenesis and biomarkers of colorectal cancer by epigenetic alteration
Chang Kyo Oh, Young-Seok Cho
Intestinal Research.2024; 22(2): 131. CrossRef
Tissue factor pathway inhibitor-2 (TFPI-2)—an underappreciated partaker in cancer and metastasis
Marek Z. Wojtukiewicz, Marta Mysliwiec, Anna Tokajuk, Joanna Kruszewska, Barbara Politynska, Anmbreen Jamroze, Anna M. Wojtukiewicz, Dean G. Tang, Kenneth V. Honn
Cancer and Metastasis Reviews.2024; 43(4): 1185. CrossRef
Detecting colorectal cancer using genetic and epigenetic biomarkers: screening and diagnosis
Yudith Annisa Ayu Rezkitha, Nur Syahadati Retno Panenggak, Maria Inge Lusida, Raissa Virgy Rianda, Isna Mahmudah, Aditya Doni Pradana, Tomohisa Uchida, Muhammad Miftahussurur
Journal of Medicine and Life.2024; 17(1): 4. CrossRef
In Silico Gene Prioritization Highlights the Significance of Bone Morphogenetic Protein 4 (BMP4) Promoter Methylation across All Methylation Clusters in Colorectal Cancer
Daša Jevšinek Skok, Nina Hauptman
International Journal of Molecular Sciences.2023; 24(16): 12692. CrossRef
Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer
Huafeng Jiang, Senjun Zhou, Gang Li
Frontiers in Pharmacology.2023;[Epub] CrossRef
A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions
Yuan Li, Bin Li, Rou Jiang, Leen Liao, Chunting Zheng, Jie Yuan, Liuhong Zeng, Kunling Hu, Yuyu Zhang, Weijian Mei, Zhigang Hong, Binyi Xiao, Lingheng Kong, Kai Han, Jinghua Tang, Wu Jiang, Zhizhong Pan, Shenyan Zhang, Peirong Ding
Cancer Medicine.2023; 12(21): 20626. CrossRef
Current Research on Molecular Biomarkers for Colorectal Cancer in Stool Samples
Patricio Órdenes, Claudio Carril Pardo, Roberto Elizondo-Vega, Karina Oyarce
Biology.2023; 13(1): 15. CrossRef
Beyond liquid biopsy: Toward non-invasive assays for distanced cancer diagnostics in pandemics
Francesco Ferrara, Sofia Zoupanou, Elisabetta Primiceri, Zulfiqur Ali, Maria Serena Chiriacò
Biosensors and Bioelectronics.2022; 196: 113698. CrossRef
Novel Diagnostic Biomarkers in Colorectal Cancer
Aneta L. Zygulska, Piotr Pierzchalski
International Journal of Molecular Sciences.2022; 23(2): 852. CrossRef
Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis
Roya Dolatkhah, Saeed Dastgiri, Mohammad Asghari Jafarabadi, Hossein Mashhadi Abdolahi, Mohammad Hossein Somi
Gastroenterología y Hepatología.2022; 45(10): 753. CrossRef
Technical considerations in PCR-based assay design for diagnostic DNA methylation cancer biomarkers
Maartje Massen, Kim Lommen, Kim A. D. Wouters, Johan Vandersmissen, Wim van Criekinge, James G. Herman, Veerle Melotte, Leo J. Schouten, Manon van Engeland, Kim M. Smits
Clinical Epigenetics.2022;[Epub] CrossRef
DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine
Nayeralsadat Fatemi, Sascha Tierling, Hamidreza Aboulkheyr Es, Maryam Varkiani, Ehsan Nazemalhosseini Mojarad, Hamid Asadzadeh Aghdaei, Jörn Walter, Mehdi Totonchi
International Journal of Cancer.2022; 151(12): 2068. CrossRef
Diagnostic accuracy of multitarget stool DNA testing for colorectal cancer screening: A systematic review and meta-analysis
Roya Dolatkhah, Saeed Dastgiri, Mohammad Asghari Jafarabadi, Hossein Mashhadi Abdolahi, Mohammad Hossein Somi
Gastroenterología y Hepatología (English Edition).2022; 45(10): 753. CrossRef
Performance evaluation of stool DNA methylation tests in colorectal cancer screening: a systematic review and meta‐analysis
Mahir Gachabayov, Edward Lebovics, Aram Rojas, Daniel M Felsenreich, Rifat Latifi, Roberto Bergamaschi
Colorectal Disease.2021; 23(5): 1030. CrossRef
Fecal Multidimensional Assay for Non-Invasive Detection of Colorectal Cancer: Fecal Immunochemical Test, Stool DNA Mutation, Methylation, and Intestinal Bacteria Analysis
Shaobo Mo, Hui Wang, Lingyu Han, Wenqiang Xiang, Weixing Dai, Pengfei Zhao, Fengchun Pei, Zhixi Su, Chengcheng Ma, Qi Li, Zhimin Wang, Sanjun Cai, Hao Wang, Rui Liu, Guoxiang Cai
Frontiers in Oncology.2021;[Epub] CrossRef
Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC
Glenn Rademakers, Maartje Massen, Alexander Koch, Muriel X. Draht, Nikkie Buekers, Kim A. D. Wouters, Nathalie Vaes, Tim De Meyer, Beatriz Carvalho, Gerrit A. Meijer, James G. Herman, Kim M. Smits, Manon van Engeland, Veerle Melotte
Clinical Epigenetics.2021;[Epub] CrossRef
Advances in Early Detection of Colorectal Cancer: A Focus on Non-invasive Biomarkers
Nadia El Kadmiri
Current Drug Targets.2021; 22(9): 1043. CrossRef
RETRACTED: Using Comorbidity Pattern Analysis to Detect Reliable Methylated Genes in Colorectal Cancer Verified by Stool DNA Test
Yi-Chiao Cheng, Po-Hsien Wu, Yen-Ju Chen, Cing-Han Yang, Jhen-Li Huang, Yu-Ching Chou, Pi-Kai Chang, Chia-Cheng Wen, Shu-Wen Jao, Hsin-Hui Huang, Yi-Hsuan Tsai, Tun-Wen Pai
Genes.2021; 12(10): 1539. CrossRef
Plausibility of an extensive use of stool DNA test for screening advanced colorectal neoplasia
Jiayi Mu, Yanqin Huang, Shanrong Cai, Qilong Li, Yongmao Song, Ying Yuan, Suzhan Zhang, Shu Zheng
Clinica Chimica Acta.2020; 501: 42. CrossRef
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Gerhard Jung, Eva Hernández-Illán, Leticia Moreira, Francesc Balaguer, Ajay Goel
Nature Reviews Gastroenterology & Hepatology.2020; 17(2): 111. CrossRef
Novel biomarkers for the diagnosis and prognosis of colorectal cancer
Hyung-Hoon Oh, Young-Eun Joo
Intestinal Research.2020; 18(2): 168. CrossRef
Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: a systematic review
Janhavi R. Raut, Zhong Guan, Petra Schrotz-King, Hermann Brenner
Clinical Epigenetics.2020;[Epub] CrossRef
Hypermethylated Promoters of Secreted Frizzled-Related Protein Genes are Associated with Colorectal Cancer
Haochang Hu, Tiangong Wang, Ranran Pan, Yong Yang, Bin Li, Cong Zhou, Jun Zhao, Yi Huang, Shiwei Duan
Pathology & Oncology Research.2019; 25(2): 567. CrossRef
BMP3 promoter hypermethylation in plasma-derived cell-free DNA in colorectal cancer patients
Parisa Rokni, Afsaneh Mojtabanezhad Shariatpanahi, Ebrahim Sakhinia, Mohammad Amin Kerachian
Genes & Genomics.2018; 40(4): 423. CrossRef
Syndecan-2 Methylation as a New Biomarker for Early Detection of Colorectal Neoplasm
Ji Hyun Kim, Sung Chul Park
Gut and Liver.2018; 12(5): 479. CrossRef

6,582 View
95 Download
26 Web of Science
26 Crossref

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study: Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong; Intest Res 2017;15(4):487-494. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.487

Abstract PDF PubReader ePub

Background/Aims

In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn's disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically focusing on the relapse rate and remission duration; also the response rate to second use when applicable.

Methods

This was a multicenter, retrospective, observational study and we enrolled CD patients who had been treated with adalimumab (ADA) according to the insurance guidelines from 2009 to 2015.

Results

A total of 54 CD patients, with follow-up of more than 6 months after the withdrawal of ADA, were enrolled. The average period of treatment with ADA was 16.7±9.7 months. After discontinuing ADA, 59.3% patients suffered a clinical relapse. In the univariate analysis, the reason for withdrawal was a risk factor for relapse (P=0.042). In the multivariate analysis, current smoker became an important risk factor for relapse (OR, 3.9; 95% CI, 1.2−14.8; P=0.044) and male sex was another risk factor (OR, 2.9; 95% CI, 1.1−8.6; P=0.049). For those 48 patients who received a second round of biologics, the clinical response was seen in 60.4%, and 1 anaphylaxis occurred.

Conclusions

Fifty-nine percent of patients experienced a relapse after discontinuing the limited period of ADA treatment, and most of them occurred within 1 year following cessation. Male sex and current smoker were risk factors for relapse. Though 60.4% of the relapse patients responded to ADA again.

Citations

Citations to this article as recorded by

Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Jia-Feng Wu, Hsu-Heng Yen, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
Intestinal Research.2024; 22(3): 250. CrossRef
Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
Advances in Digestive Medicine.2023; 10(1): 28. CrossRef
Suboptimal Outcomes and Retreatment Rate of Patients With Crohn's Disease After Forced Discontinuation of Biologics: A Nationwide Population‐Based Study
Nai‐Yu Chen, Chiao‐Hsiung Chuang, Yu‐Ching Chang, Yea‐Huei Kao Yang, Peng‐Hsu Chen, Ching‐Lan Cheng
Clinical Pharmacology & Therapeutics.2023; 114(4): 914. CrossRef
Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C
Clinical Gastroenterology and Hepatology.2022; 20(8): 1671. CrossRef
Adalimumab Efficacy for Management of Inflammatory Bowel Disease in Southwest Region of Iran
Pezhman Alavinejad, Sana Delavari, Abazar Parsi, Ali Akbar Shayesteh
Modern Care Journal.2022;[Epub] CrossRef
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
The Korean Journal of Gastroenterology.2020; 75(1): 29. CrossRef
Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
Intestinal Research.2019; 17(1): 54. CrossRef
Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
Caifang Gao, Lijuan Liu, Yangyang Zhou, Zhaoxiang Bian, Shengpeng Wang, Yitao Wang
Chinese Medicine.2019;[Epub] CrossRef
Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
Middle East Journal of Digestive Diseases.2019; 12(1): 12. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef

5,589 View
76 Download
8 Web of Science
10 Crossref

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies: Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink; Intest Res 2017;15(4):475-486. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.475

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Efficacy and safety of ustekinumab were evaluated in a Japanese subpopulation with moderately to severely active Crohn's disease (CD) in UNITI-1, UNITI-2 and IM-UNITI studies and results were compared with the overall population.

Methods

Overall, patients in UNITI-1 (Japan, n=56; failed response to tumor necrosis factor antagonist) and UNITI-2 (Japan, n=26; failed response to prior conventional therapy) were randomized to placebo or ustekinumab intravenous induction (130 mg or ~6 mg/kg) at week 0. Responders to ustekinumab induction therapy (Japan, n=21) were randomized to placebo or ustekinumab (90 mg, subcutaneous) maintenance (every 12 weeks [q12w] or 8 weeks [q8w]) in IM-UNITI. The primary endpoint was clinical response at week 6 for induction studies and clinical remission at week 44 for maintenance study.

Results

Percentage of patients achieving clinical response at week 6 was greater in ustekinumab 130 mg and ~6 mg/kg groups than in the placebo group (UNITI-1: 36.8% and 31.6% vs. 27.8%, respectively, for Japanese; 34.3% and 33.7% vs. 21.5%, respectively, for overall; UNITI-2: 37.5% and 55.6% vs. 11.1%, respectively, for Japanese; 51.7% and 55.5% vs. 28.7%, respectively, for overall). Clinical remission rate at week 44 during maintenance was greater in the ustekinumab 90 mg SC q12w and q8w groups than in the placebo group (50.0% and 55.6% vs. 25.0%, respectively, for Japanese; 48.8% and 53.1% vs. 35.9%, respectively, for overall). Efficacy and safety results observed in the Japanese subpopulation were generally consistent with those in the overall population.

Conclusions

Ustekinumab could be considered as a new therapeutic option for moderately to severely active CD in Japanese patients. Both ustekinumab induction and maintenance treatments were generally well tolerated (Clinical Trial Registration: NCT01369329, NCT01369342, NCT01369355).

Citations

Citations to this article as recorded by

Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents
Omar I. Saadah, Turki AlAmeel, Ahmed Al Sarkhy, Mohammed Hasosah, Abdulrahman Al-Hussaini, Majid A. Almadi, Badr Al-Bawardy, Talal A. Altuwaijri, Mohammed AlEdreesi, Shakir A. Bakkari, Othman R. Alharbi, Nahla A. Azzam, Abdulelah Almutairdi, Khalidah A. A
Saudi Journal of Gastroenterology.2024;[Epub] CrossRef
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef
A Retrospective Cohort Study of Clinical Features and Treatment Patterns With Ustekinumab in Patients With Crohn Disease Utilizing a Health Care Database in Japan
Yanfang Liu, Choo Hua Goh, Hong Qiu, Kuan-Chih Huang, Hsingwen Chung, Carine Saadoun
Annals of Pharmacotherapy.2023; 57(9): 1053. CrossRef
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intestinal Research.2023; 21(1): 137. CrossRef
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults
Sophie Vieujean, Edouard Louis, Silvio Danese, Laurent Peyrin-Biroulet
Expert Review of Gastroenterology & Hepatology.2023; 17(5): 413. CrossRef
Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn’s Disease: A Multicenter Observational Study
Jihye Park, Jaeyoung Chun, Hyuk Yoon, Jae Hee Cheon
Inflammatory Bowel Diseases.2022;[Epub] CrossRef
Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef
Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
Shirley Cohen-Mekelburg, Beth I. Wallace, Tony Van, Wyndy L. Wiitala, Shail M. Govani, Jennifer Burns, Rachel Lipson, Huifeng Yun, Jason Hou, James D. Lewis, Jason A. Dominitz, Akbar K. Waljee
JAMA Network Open.2021; 4(3): e210313. CrossRef
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef
Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
Seiji Yokoyama, Teita Asano, Katsumasa Nagano, Hiroaki Tsuchiya, Masayuki Takagishi, Shigeharu Tsujioka, Naomi Miura, Takayuki Matsumoto
Journal of Gastroenterology and Hepatology.2021; 36(11): 3069. CrossRef
Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice
Sushmita Negi, Sheetal Saini, Nikunj Tandel, Kiran Sahu, Ravi P.N. Mishra, Rajeev K. Tyagi
Cells.2021; 10(8): 1847. CrossRef
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intestinal Research.2021; 19(4): 386. CrossRef
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intestinal Research.2021; 19(4): 448. CrossRef
Interleukin 23 and autoimmune diseases: current and possible future therapies
Ahmad Ismail Khaled Abdo, Gee Jun Tye
Inflammation Research.2020; 69(5): 463. CrossRef
Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
Takahiro Ito, Atsuo Maemoto, Takehiko Katsurada, Hiroki Tanaka, Satoshi Motoya, Nobuhiro Ueno, Mikihiro Fujiya, Toshifumi Ashida, Daisuke Hirayama, Hiroshi Nakase
Crohn's & Colitis 360.2020;[Epub] CrossRef
Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
Caifang Gao, Lijuan Liu, Yangyang Zhou, Zhaoxiang Bian, Shengpeng Wang, Yitao Wang
Chinese Medicine.2019;[Epub] CrossRef
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
Intestinal Research.2019; 17(3): 340. CrossRef
Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease
Soo-Young Na, Won Moon
Gut and Liver.2019; 13(6): 604. CrossRef
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease
Sarah C Davies, Tran M Nguyen, Claire E Parker, John K MacDonald, Vipul Jairath, Reena Khanna
Cochrane Database of Systematic Reviews.2019;[Epub] CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Emerging Therapies: What Are Promising in the Near Future?
Geom Seog Seo, Sung Hee Lee
The Korean Journal of Gastroenterology.2018; 71(2): 81. CrossRef

6,652 View
143 Download
18 Web of Science
21 Crossref

Practice patterns and clinical significance of use of capsule endoscopy in suspected and established Crohn's disease: Yonghyun Kim, Seong Ran Jeon, Sang Myung Choi, Hyun Gun Kim, Tae Hee Lee, Jun-Hyung Cho, Yunho Jung, Wan Jung Kim, Bong Min Ko, Jin-Oh Kim, Joon Sung Lee, Moon Sung Lee; Intest Res 2017;15(4):467-474. Published online October 23, 2017; DOI: https://doi.org/10.5217/ir.2017.15.4.467

Abstract PDF PubReader ePub

Background/Aims

Although the role of capsule endoscopy (CE) in Crohn's disease (CD) has expanded, CE is not used routinely for diagnosing and evaluating CD in Korea. We aimed to investigate current patterns of practice and evaluate the clinical significance of the use of CE in CD in Korean patients.

Methods

Among 651 CE procedures performed for various indications, we retrospectively analyzed the medical records of patients who underwent CE in 57 cases of suspected CD (sCD) and 14 cases of established CD (eCD).

Results

In the sCD group, CE was most commonly used for the initial diagnosis of CD (54.4%). Capsule retention was found in only 1 patient in the eCD group (1/71, 1.4%). In the sCD group, 28.1% of patients were diagnosed with CD on the basis of CE findings; other diseases diagnosed included tuberculous enteritis (7.0%), non-steroidal anti-inflammatory drug-induced enteropathy (5.3%), and other enteritis (17.5%). Only 11.5% of patients with eCD (14/122) underwent CE. The indication for CE in the 14 patients with eCD was to assess disease extent and activity. The overall diagnostic yield of CE was 59.7%. Therapeutic strategies were changed in 70.2% of patients in the sCD group and 50% of those in the eCD group based on CE findings.

Conclusions

In clinical practice, CE was most commonly indicated for the initial diagnosis of CD and was not generally performed in patients with eCD. CE appears to be an effective diagnostic modality for evaluating sCD and is useful for determining therapeutic strategies for patients with sCD and those with eCD.

Citations

Citations to this article as recorded by

Video capsule endoscopy in inflammatory bowel disease
Kenji J.L. Limpias Kamiya, Naoki Hosoe, Yukie Hayashi, Takaaki Kawaguchi, Kaoru Takabayashi, Haruhiko Ogata, Takanori Kanai
DEN Open.2022;[Epub] CrossRef
Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
Gut and Liver.2021; 15(3): 375. CrossRef
Capsule Endoscopy in Crohn’s Disease—From a Relative Contraindication to Habitual Monitoring Tool
Adi Lahat, Ido Veisman
Diagnostics.2021; 11(10): 1737. CrossRef
Use of small bowel capsule endoscopy in clinical practice: how has it performed?
Seong Ran Jeon
The Korean Journal of Internal Medicine.2020; 35(4): 854. CrossRef
Pursuing therapeutic success in Crohn’s disease: A matter of definition, tools and longterm outcomes
Loredana Goran, Monica State, Ana Maria Negreanu, Lucian Negreanu
European Journal of Inflammation.2020; 18: 205873922096289. CrossRef
Capsule endoscopy: Current status and role in Crohn’s disease
Loredana Goran, Ana Maria Negreanu, Ana Stemate, Lucian Negreanu
World Journal of Gastrointestinal Endoscopy.2018; 10(9): 184. CrossRef
Role of capsule endoscopy in suspected or established Crohn's disease in real practice
Hyun Joo Jang
Intestinal Research.2017; 15(4): 431. CrossRef

6,073 View
73 Download
8 Web of Science
7 Crossref

Miss rate of colorectal neoplastic polyps and risk factors for missed polyps in consecutive colonoscopies: Nam Hee Kim, Yoon Suk Jung, Woo Shin Jeong, Hyo-Joon Yang, Soo-Kyung Park, Kyuyong Choi, Dong Il Park; Intest Res 2017;15(3):411-418. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.411

Abstract PDF PubReader ePub

Background/Aims

Colonoscopic polypectomy is the best diagnostic and therapeutic tool to detect and prevent colorectal neoplasms. However, previous studies have reported that 17% to 28% of colorectal polyps are missed during colonoscopy. We investigated the miss rate of neoplastic polyps and the factors associated with missed polyps from quality-adjusted consecutive colonoscopies.

Methods

We reviewed the medical records of patients who were found to have colorectal polyps at a medical examination center of the Kangbuk Samsung Hospital between March 2012 and February 2013. Patients who were referred to a single tertiary academic medical center and underwent colonoscopic polypectomy on the same day were enrolled in our study. The odds ratios (ORs) associated with polyp-related and patient-related factors were evaluated using logistic regression analyses.

Results

A total of 463 patients and 1,294 neoplastic polyps were analyzed. The miss rates for adenomas, advanced adenomas, and carcinomas were 24.1% (312/1,294), 1.2% (15/1,294), and 0% (0/1,294), respectively. Flat/sessile-shaped adenomas (adjusted OR, 3.62; 95% confidence interval [CI], 2.40–5.46) and smaller adenomas (adjusted OR, 5.63; 95% CI, 2.84– 11.15 for ≤5 mm; adjusted OR, 3.18; 95% CI, 1.60–6.30 for 6–9 mm, respectively) were more frequently missed than pedunculated/sub-pedunculated adenomas and larger adenomas. In patients with 2 or more polyps compared with only one detected (adjusted OR, 2.37; 95% CI, 1.55–3.61 for 2–4 polyps; adjusted OR, 11.52; 95% CI, 4.61–28.79 for ≥5 polyps, respectively) during the first endoscopy, the risk of missing an additional polyp was significantly higher.

Conclusions

One-quarter of neoplastic polyps was missed during colonoscopy. We encourage endoscopists to detect smaller and flat or sessile polyps by using the optimal withdrawal technique.

Citations

Citations to this article as recorded by

UM-Net: Rethinking ICGNet for polyp segmentation with uncertainty modeling
Xiuquan Du, Xuebin Xu, Jiajia Chen, Xuejun Zhang, Lei Li, Heng Liu, Shuo Li
Medical Image Analysis.2025; 99: 103347. CrossRef
The Utility of Multitarget Stool DNA Testing for Colorectal Cancer Screening After a Normal Colonoscopy
Abhinav K. Rao, Shivam Kalra, Brett Van Leer-Greenberg, Don C. Rockey
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Additional 30-Second Observation of the Right-Sided Colon for Missed Polyp Detection With Texture and Color Enhancement Imaging Compared with Narrow Band Imaging: A Randomized Trial
Naohisa Yoshida, Yoshikazu Inagaki, Yutaka Inada, Reo Kobayashi, Yuri Tomita, Hikaru Hashimoto, Osamu Dohi, Ryohei Hirose, Ken Inoue, Takaaki Murakami, Yasutaka Morimoto, Yusuke Okuyama, Yukiko Morinaga, Yoshito Itoh
American Journal of Gastroenterology.2024; 119(3): 539. CrossRef
Future Implications of Artificial Intelligence in Medical Education
Forrest Bohler, Nikhil Aggarwal, Garrett Peters, Varna Taranikanti
Cureus.2024;[Epub] CrossRef
Polyp Segmentation Using a Hybrid Vision Transformer and a Hybrid Loss Function
Evgin Goceri
Journal of Imaging Informatics in Medicine.2024; 37(2): 851. CrossRef
SAEFormer: stepwise attention emphasis transformer for polyp segmentation
Yicai Tan, Lei Chen, Chudong Zheng, Hui Ling, Xinshan Lai
Multimedia Tools and Applications.2024; 83(30): 74833. CrossRef
Polyp Segmentation With the FCB-SwinV2 Transformer
Kerr Fitzgerald, Jorge Bernal, Aymeric Histace, Bogdan J. Matuszewski
IEEE Access.2024; 12: 38927. CrossRef
Leveraging a realistic synthetic database to learn Shape-from-Shading for estimating the colon depth in colonoscopy images
Josué Ruano, Martín Gómez, Eduardo Romero, Antoine Manzanera
Computerized Medical Imaging and Graphics.2024; 115: 102390. CrossRef
DHAFormer: Dual-channel hybrid attention network with transformer for polyp segmentation
Xuejie Huang, Liejun Wang, Shaochen Jiang, Lianghui Xu, Chung-Ming Lo
PLOS ONE.2024; 19(7): e0306596. CrossRef
The Findings of Index Colonoscopy in Patients with Post-colonoscopy Colorectal Cancer (PCCRC)
Seiji Kimura
Nihon Daicho Komonbyo Gakkai Zasshi.2024; 77(8): 457. CrossRef
Detection of various gastrointestinal tract diseases through a deep learning method with ensemble ELM and explainable AI
Md. Faysal Ahamed, Md. Nahiduzzaman, Md. Rabiul Islam, Mansura Naznine, Mohamed Arselene Ayari, Amith Khandakar, Julfikar Haider
Expert Systems with Applications.2024; 256: 124908. CrossRef
A Hessian-Based Technique for Specular Reflection Detection and Inpainting in Colonoscopy Images
Khaled ELKarazle, Valliappan Raman, Caslon Chua, Patrick Then
IEEE Journal of Biomedical and Health Informatics.2024; 28(8): 4724. CrossRef
Trends in colorectal cancer surgical resection rates during the screening era: a retrospective study in Italy
Manuel Zorzi, Lucia Calciano, Nicola Gennaro, Laura Memo, Silvia Rizzato, Carmen Stocco, Emanuele D L Urso, Silvia Negro, Gaya Spolverato, Salvatore Pucciarelli, Marta Sbaraglia, Stefano Guzzinati
BMJ Open Gastroenterology.2024; 11(1): e001434. CrossRef
The Interplay among Wnt/β-catenin Family Members in Colorectal Adenomas and Surrounding Tissues
Domenica Lucia D’Antonio, Fabiana Fantini, Carmelo Moscatello, Alessio Ferrone, Stefano Scaringi, Rosa Valanzano, Ferdinando Ficari, Konstantinos Efthymakis, Matteo Neri, Gitana Maria Aceto, Maria Cristina Curia
Biomedicines.2024; 12(8): 1730. CrossRef
Review: Risk assessment of liver and biliary cancer mortality through detection of high risk polyps at colonoscopies
Abeera Tariq, Fnu Hafeezullah, Abdul Basit Khan
Digestive and Liver Disease.2024; 56(12): 2168. CrossRef
Trivariate Joint Modeling for Family Data with Longitudinal Counts, Recurrent Events and a Terminal Event with Application to Lynch Syndrome
Jingwei Lu, Grace Y. Yi, Denis Rustand, Patrick Parfrey, Laurent Briollais, Yun‐hee Choi
Statistics in Medicine.2024; 43(26): 5000. CrossRef
A complete benchmark for polyp detection, segmentation and classification in colonoscopy images
Yael Tudela, Mireia Majó, Neil de la Fuente, Adrian Galdran, Adrian Krenzer, Frank Puppe, Amine Yamlahi, Thuy Nuong Tran, Bogdan J. Matuszewski, Kerr Fitzgerald, Cheng Bian, Junwen Pan, Shijle Liu, Gloria Fernández-Esparrach, Aymeric Histace, Jorge Bernal
Frontiers in Oncology.2024;[Epub] CrossRef
Effectiveness of artificial intelligence assisted colonoscopy on adenoma and polyp miss rate: A meta-analysis of tandem RCTs
M. Maida, G. Marasco, M.H.J. Maas, D. Ramai, M. Spadaccini, E. Sinagra, A. Facciorusso, P.D. Siersema, C. Hassan
Digestive and Liver Disease.2024;[Epub] CrossRef
CafeNet: A Novel Multi‐Scale Context Aggregation and Multi‐Level Foreground Enhancement Network for Polyp Segmentation
Zhanlin Ji, Xiaoyu Li, Zhiwu Wang, Haiyang Zhang, Na Yuan, Xueji Zhang, Ivan Ganchev
International Journal of Imaging Systems and Technology.2024;[Epub] CrossRef
An optimized deep focused U-Net model for image segmentation
Haroon Haider Khan, Majid Iqbal Khan
Neural Computing and Applications.2024;[Epub] CrossRef
Efficacy of colonoscopic re-examination across the entire colon: a randomized controlled trial
Dong Seok Lee, Jeong-Seon Ji, Tae-Geun Gweon, Myeongsook Seo, Hwang Choi
Surgical Endoscopy.2024; 38(11): 6711. CrossRef
A lighter hybrid feature fusion framework for polyp segmentation
He Xue, Luo Yonggang, Liu Min, Li Lin
Scientific Reports.2024;[Epub] CrossRef
Significant Missed Polyps in the UK Bowel Cancer Screening Programme (BCSP): A Retrospective Analysis of Prevalence and Contributing Factors
Anita Golash, Kevin Yoong, Ramasamy Saravanan
Cureus.2024;[Epub] CrossRef
Fluorescence-guided tumor visualization of colorectal cancer using tumor-initiating probe yellow in preclinical models
Sun Young Kim, Jinhyeon Kim, Hajung Kim, Young-Tae Chang, Hwa-Young Kwon, Jong Lyul Lee, Yong Sik Yoon, Chan Wook Kim, Seung-Mo Hong, Jin-ho Shin, Seung Wook Hong, Sung Wook Hwang, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Byung Ho Son, Seung-Jae Myun
Scientific Reports.2024;[Epub] CrossRef
An ensemble framework of deep neural networks for colorectal polyp classification
Farah Younas, Muhammad Usman, Wei Qi Yan
Multimedia Tools and Applications.2023; 82(12): 18925. CrossRef
Effect of computer‐aided colonoscopy on adenoma miss rates and polyp detection: A systematic review and meta‐analysis
Sagar Shah, Nathan Park, Nabil El Hage Chehade, Anastasia Chahine, Marc Monachese, Amelie Tiritilli, Zain Moosvi, Ronald Ortizo, Jason Samarasena
Journal of Gastroenterology and Hepatology.2023; 38(2): 162. CrossRef
Comparison of missed adenomas in deep-sedated and unsedated colonoscopy: A multicenter retrospective study
Yue Sui, Yanhua Zheng, Qing Wang, Jieping Lv, Hongjin Wang, Qing Wen, Zhenzhen Wang, Guanfeng Wang, Hui Jia, Fengzhen Cao, Naping Wang, Junlian Hao, Yiping Zhang, Xiaopeng Wu, Haihua Chen, Junhui Lu, Xing Chen
European Journal of Internal Medicine.2023; 110: 48. CrossRef
A Real-Time Polyp-Detection System with Clinical Application in Colonoscopy Using Deep Convolutional Neural Networks
Adrian Krenzer, Michael Banck, Kevin Makowski, Amar Hekalo, Daniel Fitting, Joel Troya, Boban Sudarevic, Wolfgang G. Zoller, Alexander Hann, Frank Puppe
Journal of Imaging.2023; 9(2): 26. CrossRef
Robust real-time polyp detection system design based on YOLO algorithms by optimizing activation functions and hyper-parameters with artificial bee colony (ABC)
Ahmet Karaman, Ishak Pacal, Alper Basturk, Bahriye Akay, Ufuk Nalbantoglu, Seymanur Coskun, Omur Sahin, Dervis Karaboga
Expert Systems with Applications.2023; 221: 119741. CrossRef
Efficient Gastrointestinal Disease Classification Using Pretrained Deep Convolutional Neural Network
Muhammad Nouman Noor, Muhammad Nazir, Sajid Ali Khan, Oh-Young Song, Imran Ashraf
Electronics.2023; 12(7): 1557. CrossRef
The basis and implications of diverging approaches to colorectal adenoma surveillance in the West
Tsai‐Wing Ow, Edmund Tse, Guru Iyngkaran, Finlay Macrae
Internal Medicine Journal.2023; 53(4): 635. CrossRef
Investigation of artificial intelligence integrated fluorescence endoscopy image analysis with indocyanine green for interpretation of precancerous lesions in colon cancer
Jinhyeon Kim, Hajung Kim, Yong Sik Yoon, Chan Wook Kim, Seung-Mo Hong, Sungjee Kim, Doowon Choi, Jihyun Chun, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Sun Young Kim, Seung-Jae Myung,
PLOS ONE.2023; 18(5): e0286189. CrossRef
Linked color imaging versus conventional white light colonoscopy for the detection of colorectal polyps
Jun Watanabe, Takeshi Kanno, Eiichi Kakehi, Kazuma Rifu, Takehiro Kagaya, Kazuhiko Kotani, Yuki Kataoka
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef
RETRACTED ARTICLE: A dynamic loss function for improved semantic segmentation
Haroon Haider Khan, Majid Iqbal Khan
Soft Computing.2023;[Epub] CrossRef
Improved Colorectal Polyp Segmentation Using Enhanced MA-NET and Modified Mix-ViT Transformer
Khaled Elkarazle, Valliappan Raman, Patrick Then, Caslon Chua
IEEE Access.2023; 11: 69295. CrossRef
Localization and Classification of Gastrointestinal Tract Disorders Using Explainable AI from Endoscopic Images
Muhammad Nouman Noor, Muhammad Nazir, Sajid Ali Khan, Imran Ashraf, Oh-Young Song
Applied Sciences.2023; 13(15): 9031. CrossRef
Near-Infrared Imaging of Colonic Adenomas In Vivo Using Orthotopic Human Organoids for Early Cancer Detection
Xiaoli Wu, Chun-Wei Chen, Sangeeta Jaiswal, Tse-Shao Chang, Ruoliu Zhang, Michael K. Dame, Yuting Duan, Hui Jiang, Jason R. Spence, Sen-Yung Hsieh, Thomas D. Wang
Cancers.2023; 15(19): 4795. CrossRef
Comparative Analysis of Machine Learning Models for Image Detection of Colonic Polyps vs. Resected Polyps
Adriel Abraham, Rejath Jose, Jawad Ahmad, Jai Joshi, Thomas Jacob, Aziz-ur-rahman Khalid, Hassam Ali, Pratik Patel, Jaspreet Singh, Milan Toma
Journal of Imaging.2023; 9(10): 215. CrossRef
Wide-field endoscope accessory for multiplexed fluorescence imaging
Gaoming Li, Miki Lee, Tse-Shao Chang, Joonyoung Yu, Haijun Li, Xiyu Duan, Xiaoli Wu, Sangeeta Jaiswal, Shuo Feng, Kenn R. Oldham, Thomas D. Wang
Scientific Reports.2023;[Epub] CrossRef
Analysis and research on intelligent manufacturing medical product design and intelligent hospital system dynamics based on machine learning under big data
Zongxin Liu, Jiaozi Pu
Enterprise Information Systems.2022; 16(2): 193. CrossRef
Application of multimedia network english listening model based on confidence learning algorithm for speech recognition
Yingting Zhang, Zewei Huang
International Journal of System Assurance Engineering and Management.2022; 13(S3): 1091. CrossRef
Unified Focal loss: Generalising Dice and cross entropy-based losses to handle class imbalanced medical image segmentation
Michael Yeung, Evis Sala, Carola-Bibiane Schönlieb, Leonardo Rundo
Computerized Medical Imaging and Graphics.2022; 95: 102026. CrossRef
Colonoscopic image synthesis with generative adversarial network for enhanced detection of sessile serrated lesions using convolutional neural network
Dan Yoon, Hyoun-Joong Kong, Byeong Soo Kim, Woo Sang Cho, Jung Chan Lee, Minwoo Cho, Min Hyuk Lim, Sun Young Yang, Seon Hee Lim, Jooyoung Lee, Ji Hyun Song, Goh Eun Chung, Ji Min Choi, Hae Yeon Kang, Jung Ho Bae, Sungwan Kim
Scientific Reports.2022;[Epub] CrossRef
Endo‐wing versus transparent hood‐assisted colonoscopy for colorectal adenoma detection: A randomized controlled trial
Kazuya Miyaguchi, Yoshikazu Tsuzuki, Nobutaka Hirooka, Rie Shiomi, Hideki Ohgo, Hidetomo Nakamoto, Hiroyuki Imaeda
Journal of Gastroenterology and Hepatology.2022; 37(4): 766. CrossRef
AI and Clinical Decision Making: The Limitations and Risks of Computational Reductionism in Bowel Cancer Screening
Saleem Ameen, Ming-Chao Wong, Kwang-Chien Yee, Paul Turner
Applied Sciences.2022; 12(7): 3341. CrossRef
BlazeNeo: Blazing Fast Polyp Segmentation and Neoplasm Detection
Nguyen S. An, Phan N. Lan, Dao V. Hang, Dao V. Long, Tran Q. Trung, Nguyen T. Thuy, Dinh V. Sang
IEEE Access.2022; 10: 43669. CrossRef
Establishment and evaluation of a nomogram predicting risks of missed diagnoses of colorectal polyps
Xiaobo Wang, Haiyang Guo, Yong Tang, Lin Chen, Xianfei Wang
BMC Gastroenterology.2022;[Epub] CrossRef
Evaluation of the efficacy of 1 L polyethylene glycol plus ascorbic acid and an oral sodium sulfate solution: A multi-center, prospective randomized controlled trial
Jung Hun Woo, Hoon Sup Koo, Dae Sung Kim, Jeong Eun Shin, Yunho Jung, Kyu Chan Huh
Medicine.2022; 101(35): e30355. CrossRef
Correlation between Surrogate Quality Indicators for Adenoma Detection Rate and Adenoma Miss Rate in Qualified Colonoscopy, CORE Study: KASID Multicenter Study
Jae Hee Han, Hyun Gun Kim, Eu Mi Ahn, Suyeon Park, Seong Ran Jeon, Jae Myung Cha, Min Seob Kwak, Yunho Jung, Jeong Eun Shin, Hyun Deok Shin, Young-Seok Cho
Gut and Liver.2022; 16(5): 716. CrossRef
Endoscopy Lifetime Systems Architecture: Scoping Out the Past to Diagnose the Future Technology
Craig M. Browning, Robert Cloutier, Thomas C. Rich, Silas J. Leavesley
Systems.2022; 10(5): 189. CrossRef
A stacking-based artificial intelligence framework for an effective detection and localization of colon polyps
Carina Albuquerque, Roberto Henriques, Mauro Castelli
Scientific Reports.2022;[Epub] CrossRef
Effect of water exchange method on adenoma miss rate of patients undergoing selective polypectomy: A randomized controlled trial
Gui Ren, Xiangping Wang, Hui Luo, Shaowei Yao, Shuhui Liang, Linhui Zhang, Tao Dong, Long Chen, Qin Tao, Xuegang Guo, Ying Han, Yanglin Pan
Digestive and Liver Disease.2021; 53(5): 625. CrossRef
Feature Point Tracking-Based Localization of Colon Capsule Endoscope
Jürgen Herp, Ulrik Deding, Maria M. Buijs, Rasmus Kroijer, Gunnar Baatrup, Esmaeil S. Nadimi
Diagnostics.2021; 11(2): 193. CrossRef
Risk factors associated with missed colorectal lesions in colonoscopy and impact of colonoscopy with anesthesia on miss rate
Haibin Dong, Yutang Ren, Bo Jiang
Scandinavian Journal of Gastroenterology.2021; 56(4): 484. CrossRef
Diagnostic Accuracy of Artificial Intelligence and Computer-Aided Diagnosis for the Detection and Characterization of Colorectal Polyps: Systematic Review and Meta-analysis
Scarlet Nazarian, Ben Glover, Hutan Ashrafian, Ara Darzi, Julian Teare
Journal of Medical Internet Research.2021; 23(7): e27370. CrossRef
Focus U-Net: A novel dual attention-gated CNN for polyp segmentation during colonoscopy
Michael Yeung, Evis Sala, Carola-Bibiane Schönlieb, Leonardo Rundo
Computers in Biology and Medicine.2021; 137: 104815. CrossRef
Comparison of adenoma detection by colonoscopy between polypectomy performed during both insertion and withdrawal versus during withdrawal only: a multicenter, randomized, controlled trial
Tae-Geun Gweon, Seung-Woo Lee, Jeong-Seon Ji, Jeong Rok Lee, Joon Sung Kim, Byung-Wook Kim, Hwang Choi
Surgical Endoscopy.2020; 34(12): 5461. CrossRef
Water Exchange (WE) and Quality Improvement—Enhanced Advanced Adenoma Detection
Felix W. Leung, Malcolm Koo, Hui Jia, Joseph W. Leung, Sergio Cadoni, Premysl Falt, Yu-Hsi Hsieh, Chi-Tan Hu, Yanglin Pan, Franco Radaelli
Journal of Clinical Gastroenterology.2020; 54(3): 212. CrossRef
Tubular Locomotion and Positioning Using Tip Eversion for Endoscopy
Ankit Saxena, Eric M. Pauli, Randy S. Haluck, Barry Fell, Jason Moore
Journal of Medical Devices.2020;[Epub] CrossRef
Molecular Aspects of Colorectal Adenomas: The Interplay among Microenvironment, Oxidative Stress, and Predisposition
Gitana Maria Aceto, Teresa Catalano, Maria Cristina Curia
BioMed Research International.2020; 2020: 1. CrossRef
Impact of Inadequate Bowel Cleansing on Colonoscopic Findings in Routine Screening Practice
Tobias Niedermaier, Efrat L. Amitay, Anton Gies, Korbinian Weigl, Michael Hoffmeister, Hermann Brenner
Clinical and Translational Gastroenterology.2020; 11(4): e00169. CrossRef
Polyp Segmentation with Fully Convolutional Deep Neural Networks—Extended Evaluation Study
Yunbo Guo, Jorge Bernal, Bogdan J. Matuszewski
Journal of Imaging.2020; 6(7): 69. CrossRef
A comprehensive review of deep learning in colon cancer
Ishak Pacal, Dervis Karaboga, Alper Basturk, Bahriye Akay, Ufuk Nalbantoglu
Computers in Biology and Medicine.2020; 126: 104003. CrossRef
Artificial intelligence technologies for the detection of colorectal lesions: The future is now
Simona Attardo, Viveksandeep Thoguluva Chandrasekar, Marco Spadaccini, Roberta Maselli, Harsh K Patel, Madhav Desai, Antonio Capogreco, Matteo Badalamenti, Piera Alessia Galtieri, Gaia Pellegatta, Alessandro Fugazza, Silvia Carrara, Andrea Anderloni, Piet
World Journal of Gastroenterology.2020; 26(37): 5606. CrossRef
Training a computer-aided polyp detection system to detect sessile serrated adenomas using public domain colonoscopy videos
Taibo Li, Jeremy R. Glissen Brown, Kelovoulos Tsourides, Nadim Mahmud, Jonah M. Cohen, Tyler M. Berzin
Endoscopy International Open.2020; 08(10): E1448. CrossRef
PICCOLO White-Light and Narrow-Band Imaging Colonoscopic Dataset: A Performance Comparative of Models and Datasets
Luisa F. Sánchez-Peralta, J. Blas Pagador, Artzai Picón, Ángel José Calderón, Francisco Polo, Nagore Andraka, Roberto Bilbao, Ben Glover, Cristina L. Saratxaga, Francisco M. Sánchez-Margallo
Applied Sciences.2020; 10(23): 8501. CrossRef
Efficacy of 1.2 L polyethylene glycol plus ascorbic acid for bowel preparations
Hiroyuki Tamaki, Teruyo Noda, Masahiro Morita, Akina Omura, Atsushi Kubo, Chikara Ogawa, Toshihiro Matsunaka, Mitsushige Shibatoge
World Journal of Clinical Cases.2019; 7(4): 452. CrossRef
Multimodal endoscopic system based on multispectral and photometric stereo imaging and analysis
Jihun Kim, Hasan Al Faruque, Sewoong Kim, Eunjoo Kim, Jae Youn Hwang
Biomedical Optics Express.2019; 10(5): 2289. CrossRef
Blue Laser Imaging, Blue Light Imaging, and Linked Color Imaging for the Detection and Characterization of Colorectal Tumors
Naohisa Yoshida, Osamu Dohi, Ken Inoue, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Ken Inoue, Yuji Naito, Yutaka Inada, Kiyoshi Ogiso, Yukiko Morinaga, Mitsuo Kishimoto, Rafiz Abdul Rani, Yoshito Itoh
Gut and Liver.2019; 13(2): 140. CrossRef
Application of OCT in the Gastrointestinal Tract
Nicholas S. Samel, Hiroshi Mashimo
Applied Sciences.2019; 9(15): 2991. CrossRef
Near-Infrared Fluorescent Activated Polymeric Probe for Imaging Intraluminal Colorectal Cancer Tumors
Eva Kopansky-Groisman, Inga Kogan-Zviagin, Osnat Sella-Tavor, Mor Oron-Herman, Ayelet David
Biomacromolecules.2019; 20(9): 3547. CrossRef
Predictive factors for missed adenoma on repeat colonoscopy in patients with suboptimal bowel preparation on initial colonoscopy: A KASID multicenter study
Ji Young Chang, Chang Mo Moon, Hyun Jung Lee, Hyo-Joon Yang, Yunho Jung, Sang Wook Kim, Sung-Ae Jung, Jeong-Sik Byeon, Frank T. Kolligs
PLOS ONE.2018; 13(4): e0195709. CrossRef
Cimetropium bromide does not improve polyp and adenoma detection during colonoscope withdrawal
Peel Jung, Su B. Park, Hyung W. Kim, Dae H. Kang, Cheol W. Choi, Su J. Kim, Hyeong S. Nam, Dae G. Ryu, Joung B. Hong, Dong J. Kim
Medicine.2018; 97(25): e11253. CrossRef
Dielectric properties of colon polyps, cancer, and normal mucosa: Ex vivo measurements from 0.5 to 20 GHz
Marta Guardiola, Santiago Buitrago, Glòria Fernández‐Esparrach, Joan M. O'Callaghan, Jordi Romeu, Miriam Cuatrecasas, Henry Córdova, Miguel Ángel González Ballester, Oscar Camara
Medical Physics.2018; 45(8): 3768. CrossRef
Quality is the key for emerging issues of population-based colonoscopy screening
Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
Intestinal Research.2018; 16(1): 48. CrossRef
An Additional 30-s Observation of the Right-Sided Colon with Narrow Band Imaging Decreases Missed Polyps: A Pilot Study
Naohisa Yoshida, Ken Inoue, Ritsu Yasuda, Ryohei Hirose, Osamu Dohi, Yuji Naito, Takaaki Murakami, Yutaka Inada, Kiyoshi Ogiso, Yukiko Morinaga, Mitsuo Kishimoto, Rafiz Abdul Rani, Yoshito Itoh
Digestive Diseases and Sciences.2018; 63(12): 3457. CrossRef
Quality is the Key for Emerging Issues of Population-Based Colonoscopy Screening
Jin Young Yoon, Jae Myung Cha, Yoon Tae Jeen
Clinical Endoscopy.2018; 51(1): 50. CrossRef
Additional Thirty Seconds Observation with Linked Color Imaging Improves Detection of Missed Polyps in the Right-Sided Colon
Naohisa Yoshida, Yutaka Inada, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Ken Inoue, Osamu Dohi, Yuji Naito, Kiyoshi Ogiso, Yukiko Morinaga, Mitsuo Kishimoto, Eiichi Konishi, Yoshito Itoh
Gastroenterology Research and Practice.2018; 2018: 1. CrossRef
Molecular Imaging of Colorectal Tumors by Targeting Colon Cancer Secreted Protein-2 (CCSP-2)
Jaeil Kim, Eun-ju Do, Helen Moinova, Sang Mun Bae, Ja Young Kang, Seung-Mo Hong, Stephen P. Fink, Jinmyoung Joo, Young-Ah Suh, Se Jin Jang, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Jaewon Choe, Suk-Kyun Yang, Sanfo
Neoplasia.2017; 19(10): 805. CrossRef

11,095 View
103 Download
92 Web of Science
79 Crossref

Clinical characteristics of patients with serrated polyposis syndrome in Korea: comparison with Western patients: Eun Ran Kim, Jaryong Jeon, Jin Hee Lee, Yoon Jung Lee, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim; Intest Res 2017;15(3):402-410. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.402

Abstract PDF PubReader ePub

Background/Aims

Serrated polyposis syndrome (SPS) has been shown to increase the risk of colorectal cancer (CRC). However, little is known about the characteristics of Asian patients with SPS. This study aimed to identify the clinicopathological features and risk of CRC in Korean patients with SPS as well as the differences between Korean and Western patients based on a literature review.

Methods

This retrospective study included 30 patients with SPS as defined by World Health Organization classification treated at Samsung Medical Center, Korea, between March 1999 and May 2011.

Results

Twenty patients (67%) were male. The median patient age at diagnosis was 56 years (range, 39–76 years). A total of 702 polyps were identified during a median follow-up of 43 months (range, 0–149 months). Serrated polyps were noted more frequently in the distal colon (298/702, 55%). However, large serrated polyps and serrated adenomas were mainly distributed throughout the proximal colon (75% vs. 25% and 81% vs. 19%, respectively); 73.3% had synchronous adenomatous polyps. The incidence of CRC was 10% (3/30 patients), but no interval CRC was detected. A total of 87% of the patients underwent esophagogastroduodenoscopy and 19.2% had significant lesions.

Conclusions

The phenotype of SPS in Korean patients is different from that of Western patients. In Korean patients, SPS is more common in men, there were fewer total numbers of serrated adenoma/polyps, and the incidence of CRC was lower than that in Western patients. Korean patients tend to more frequently have abnormal gastric lesions. However, the prevalence of synchronous adenomatous polyps is high in both Western and Korean patients.

Citations

Citations to this article as recorded by

Risk of Colorectal Cancer in Serrated Polyposis Syndrome: A Systematic Review and Meta-analysis
Charles Muller, Akihiro Yamada, Sachie Ikegami, Haider Haider, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba
Clinical Gastroenterology and Hepatology.2022; 20(3): 622. CrossRef
Synchronized early gastric cancer occurred in a patient with serrated polyposis syndrome: A case report
Ying-Ze Ning, Guan-Yi Liu, Xiao-Long Rao, Yong-Chen Ma, Long Rong
World Journal of Clinical Cases.2022; 10(8): 2644. CrossRef
Usefulness of narrow-band imaging for the detection of remnant sessile-serrated adenoma (SSA) tissue after endoscopic resection: the KASID multicenter study
Yunho Jung, Jung Rock Moon, Seong Ran Jeon, Jae Myung Cha, Hyo-Joon Yang, Suyeon Park, Yumi Ahn, Jeong-Sik Byeon, Hyun Gun Kim
Surgical Endoscopy.2021; 35(9): 5217. CrossRef
Serrated Polyposis Syndrome with a Synchronous Colon Adenocarcinoma Treated by an Endoscopic Mucosal Resection
Sang Hoon Lee, Sung Joon Lee, Sung Chul Park, Seung-Joo Nam, Myeong Ho Kang, Tae Suk Kim, Seung Koo Lee
The Korean Journal of Gastroenterology.2020; 76(3): 159. CrossRef

7,226 View
69 Download
7 Web of Science
4 Crossref

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial: Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M. Robinson, Roopal B. Thakkar, Toshifumi Hibi; Intest Res 2017;15(3):395-401. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.395

Abstract PDF PubReader ePub

Background/Aims

Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671).

Methods

Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, followed by 40 mg every other week until the end of the study. Long-term safety and all adverse events (AEs) were examined. The efficacy was assessed on the basis of marked improvement (MI) and complete remission (CR) using a composite efficacy index, which combined global gastrointestinal symptoms and endoscopic assessments.

Results

Twenty patients were enrolled in this study; 15 patients received adalimumab treatment until study completion. The incidence of AEs through week 100 was 544.4 events/100 person-years, which was comparable to the incidence through week 52 (560.4 events/100 person-years). No unexpected trend was observed and adalimumab was well tolerated. At weeks 52 and 100, 60.0% and 40.0% of patients showed MI, respectively, and 20.0% and 15.0% of patients showed CR, respectively.

Conclusions

This report demonstrates 2 years safety and effectiveness of adalimumab in intestinal BD patients. Patients with intestinal BD refractory to conventional treatment receiving up to 2 years of adalimumab treatment demonstrated safety outcomes consistent with the known profile of adalimumab, and the treatment led to sustained reduction of clinical and endoscopic disease activity.

Citations

Citations to this article as recorded by

Positive antiphospholipid antibodies and pulmonary embolism in a patient with adalimumab-induced lupus
Masaaki Uehara, Shinya Matsushita, Satsuki Aochi, Motohisa Yamamoto
Modern Rheumatology Case Reports.2023; 7(1): 68. CrossRef
Hemorrhagic gastric ulcer in a patient with Behcet's disease successfully treated with infliximab
Shun Fujiwara, Ami Kawamoto, Maiko Motobayashi, Shuji Hibiya, Kento Takenaka, Hiromichi Shimizu, Eiko Saito, Toshimitsu Fujii, Masakazu Nagahori, Daisuke Kawata, Natsuka Umezawa, Tadashi Hosoya, Shinsuke Yasuda, Kazuo Ohtsuka, Ryuichi Okamoto
DEN Open.2023;[Epub] CrossRef
Treatment Options in Pediatric Behçet’s Disease
Teresa Giani, Angela Flavia Luppino, Giovanna Ferrara
Pediatric Drugs.2023; 25(2): 165. CrossRef
Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
Jae Hee Cheon, Hyun-Soo Kim, Dong Soo Han, Sung Kook Kim, Sung Jae Shin, Joo Sung Kim, Byong Duk Ye, Geun Am Song, YoungJa Lee, Youngdoe Kim, Yoosun Lee, Won Ho Kim
Gut and Liver.2023; 17(5): 777. CrossRef
Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
BMC Gastroenterology.2023;[Epub] CrossRef
The efficacy and safety of anti‐tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta‐analysis
Mengyuan Zhang, Jinjing Liu, Tingting Liu, Wei Han, Xiaoyin Bai, Gechong Ruan, Hong Lv, Huijun Shu, Yue Li, Ji Li, Bei Tan, Weiyang Zheng, Hui Xu, Wenjie Zheng, Hong Yang, Jiaming Qian
Journal of Gastroenterology and Hepatology.2022; 37(4): 608. CrossRef
Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
Haruka Miyazaki, Daisuke Watanabe, Norihiro Okamoto, Eri Tokunaga, Yuna Ku, Haruka Takenaka, Namiko Hoshi, Makoto Ooi, Yuzo Kodama
BMC Gastroenterology.2022;[Epub] CrossRef
New insights on multigenic autoinflammatory diseases
Petros Efthimiou, Olga Petryna, Priscila Nakasato, Apostolos Kontzias
Therapeutic Advances in Musculoskeletal Disease.2022;[Epub] CrossRef
Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis
Shukai Zhan, Caiguang Liu, Na Li, Tong Li, Zhenyi Tian, Min Zhao, Dongxuan Wu, Minhu Chen, Zhirong Zeng, Xiaojun Zhuang
Therapeutic Advances in Gastroenterology.2022;[Epub] CrossRef
Clinical Manifestations and Management of Pediatric Behçet’s Disease
Ya-Chiao Hu, Bor-Luen Chiang, Yao-Hsu Yang
Clinical Reviews in Allergy & Immunology.2021; 61(2): 171. CrossRef
Advances in Management of Intestinal Behçet’s Disease: A Perspective From Gastroenterologists
Jae Hee Cheon
Journal of Rheumatic Diseases.2021; 28(1): 4. CrossRef
Mucosal healing in intestinal Behçet's disease: A systematic review and meta‐analysis
Liang Gong, Yue Lun Zhang, Lu Xi Sun, Guo Rong Chen, Dong Wu
Journal of Digestive Diseases.2021; 22(2): 83. CrossRef
Experimental Therapeutic Solutions for Behcet’s Disease
Burçin Cansu Bozca, Erkan Alpsoy
Journal of Experimental Pharmacology.2021; Volume 13: 127. CrossRef
Advances in the Treatment of Behcet’s Disease
Fatma Alibaz-Oner, Haner Direskeneli
Current Rheumatology Reports.2021;[Epub] CrossRef
Behçet Disease: An Update for Dermatologists
Erkan Alpsoy, Burcin Cansu Bozca, Asli Bilgic
American Journal of Clinical Dermatology.2021; 22(4): 477. CrossRef
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi
Intestinal Research.2021; 19(3): 301. CrossRef
Juvenile-onset Behçet's syndrome and mimics
Clare E. Pain
Clinical Immunology.2020; 214: 108381. CrossRef
Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents
Yehyun Park, Jae Hee Cheon
Current Gastroenterology Reports.2020;[Epub] CrossRef
An Overview of Conventional and Recent Treatment Options for Behcet’s Disease
Kader Cetin Gedik, Micol Romano, Roberta A. Berard, Erkan Demirkaya
Current Treatment Options in Rheumatology.2020; 6(2): 99. CrossRef
Safety of systemic treatments for Behçet’s syndrome
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini, Florenzo Iannone
Expert Opinion on Drug Safety.2020; 19(10): 1269. CrossRef
The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions
Harutaka Kambayashi, Teppei Omori, Satomi Saito, Shun Murasugi, Hiroyuki Kashiwagi, Ayumi Ito, Maria Yonezawa, Shinichi Nakamura, Katsutoshi Tokushige
Internal Medicine.2020; 59(19): 2343. CrossRef
Successful closure of ileostomy in a patient with intestinal Behçet's disease after therapy with adalimumab
Zhe Yan, Bei-Bei Cui, Yong-Yang Yu, Geng Yin, Xiao-Min Cen, Qi-Bing Xie
Medicine.2019; 98(9): e14624. CrossRef
Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet’s disease
Naomi Sugimura, Tsutomu Mizoshita, Tomoya Sugiyama, Shozo Togawa, Tomokatsu Miyaki, Taketo Suzuki, Satoshi Tanida, Hiromi Kataoka, Makoto Sasaki
Digestive and Liver Disease.2019; 51(7): 967. CrossRef
Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet’s disease
Ippei Miyagawa, Kazuhisa Nakano, Shigeru Iwata, Shingo Nakayamada, Kazuyoshi Saito, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Akio Kawabe, Yusuke Miyazaki, Yoshiya Tanaka
Arthritis Research & Therapy.2019;[Epub] CrossRef
Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan
Ya-Chiao Hu, Yao-Hsu Yang, Yu-Tsan Lin, Li-Chieh Wang, Hsin-Hui Yu, Jyh-Hong Lee, Bor-Luen Chiang
BMC Pediatrics.2019;[Epub] CrossRef
Management of Behçet's disease
Fatma Alibaz-Oner, Amr H. Sawalha, Haner Direskeneli
Current Opinion in Rheumatology.2018; 30(3): 238. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
Gastrointestinal Involvement in Behçet Disease
Ibrahim Hatemi, Gulen Hatemi, Aykut Ferhat Çelik
Rheumatic Disease Clinics of North America.2018; 44(1): 45. CrossRef
Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease
Jihye Park, Jae Hee Cheon
Gut and Liver.2018; 12(6): 623. CrossRef
Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
Jihye Park, Jae Hee Cheon
Intestinal Research.2017; 15(3): 263. CrossRef

6,470 View
87 Download
32 Web of Science
30 Crossref

Familial aggregation of inflammatory bowel disease in patients with ulcerative colitis: Akshita Gupta, Sawan Bopanna, Saurabh Kedia, Dawesh Prakash Yadav, Sandeep Goyal, Saransh Jain, Govind Makharia, Vineet Ahuja; Intest Res 2017;15(3):388-394. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.388

Abstract PDF PubReader ePub

Background/Aims

Familial occurrence of inflammatory bowel disease (IBD) is well documented. Reports from Western countries have shown a higher familial occurrence of ulcerative colitis (UC) in first- and second-degree relatives than that in the Asian UC population. No data are currently available from the Indian subcontinent in this regard. We present our data on the familial aggregation of UC.

Methods

Records of patients with UC followed at the Inflammatory Bowel Disease Clinic at the All India Institute of Medical Sciences, New Delhi from August 2004 to January 2016 were reviewed. Details regarding the prevalence of family history and characteristics of these patients were recorded. Affected family members were contacted and disease characteristics were noted for assessment of familial aggregation.

Results

Of the 2,058 UC patients included in the analysis, a positive family history of IBD was confirmed in 31 patients (1.5%), 24 (77.4%) of whom had only first-degree relatives affected. All the affected relatives had UC and none had Crohn's disease. Among first-degree relatives, siblings were found to have the highest prevalence of IBD (53.3%), followed by parents (26.7%).

Conclusions

The probability of occurrence of IBD in family members of affected North Indian UC patients is lower than that reported in Western populations.

Citations

Citations to this article as recorded by

Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection
Shadi Tabbarah, Hakam Sulaiman, Frank Ansah Owusu, Megha Rajeev Joshi, Nitheesha Reddy Marepalli, Nohelia Pino, Samra Saleem Azam, Aaliya Ali Ahmed, José Abraham Suárez Álvarez
Cureus.2024;[Epub] CrossRef
Childhood antibiotics as a risk factor for Crohn's disease: The ENIGMA International Cohort Study
Joyce W Y Mak, Sun Yang, Annalise Stanley, Xiaoqing Lin, Mark Morrison, Jessica Y L Ching, Junkun Niu, Amy L Wilson‐O'Brien, Rui Feng, Whitney Tang, Amy L Hamilton, Leo Or, Gina L Trakman, Winnie Y Y Lin, Joseph J Y Sung, Ming Hu Chen, Yinglei Mao, Michae
JGH Open.2022; 6(6): 369. CrossRef
Does the road to primary prevention of inflammatory bowel disease start from childhood?
Saurabh Kedia, Vineet Ahuja
JGH Open.2022; 6(6): 365. CrossRef
Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis
Junfeng Zou, Chen Liu, Shu Jiang, Dawei Qian, Jinao Duan, Anthony R. Richardson
Infection and Immunity.2021;[Epub] CrossRef
Factors Affecting Ulcerative Colitis Flare-Ups: Associations With Smoking Habits and Other Patient Characteristics
Nadim H Malibary, Mohammed A Ezzat, Ahmed M Mogharbel, Khalid A Kouzaba, Abdulaziz A Alkadi, Usama H Malki, Sultan M Gharib, Faisal M Altowairqi, Omar I Saadah, Mahmoud H Mosli
Cureus.2021;[Epub] CrossRef
Inflammatory bowel disease: An Indian perspective
Mayank Jain, Jayanthi Venkataraman
Indian Journal of Medical Research.2021; 153(4): 421. CrossRef
Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior
Rupa Banerjee, Partha Pal, Susan Hutfless, B Girish Ganesh, D Nageshwar Reddy
Intestinal Research.2019; 17(4): 486. CrossRef
Decreased Breg/Th17 Ratio Improved the Prognosis of Patients with Ulcerative Colitis
Xue Bing, Liang Linlang, Chen Keyan
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef
Is the emergence of inflammatory bowel disease a prime example of “the third epidemiological transition”?
Saurabh Kedia, Vineet Ahuja
Indian Journal of Gastroenterology.2018; 37(3): 183. CrossRef

6,213 View
39 Download
10 Web of Science
9 Crossref

Ophthalmologic manifestations in patients with inflammatory bowel disease: Hye Jin Lee, Hyun Joo Song, Jin Ho Jeong, Heung Up Kim, Sun-Jin Boo, Soo-Young Na; Intest Res 2017;15(3):380-387. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.380

Abstract PDF PubReader ePub

Background/Aims

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), has been reported to have various ophthalmologic manifestations. The aim of this study was to evaluate the prevalence of ophthalmologic manifestations associated with IBD in Korea.

Methods

Sixty-one patients were examined between May 2013 and October 2014. We performed complete ophthalmologic examinations.

Results

Findings included 36 patients with CD and 25 with UC. The mean age of the patients was 34±16 years and disease duration was 45.3±23.9 months. Ophthalmologic manifestations were positive in 44 cases. Primary complication was diagnosed in 5 cases, as follows; iritis in 2 cases, episcleritis in one case, iritis with optic neuritis in 1 case, and serous retinal detachment in 1 case, without secondary complications. The most common coincidental complication was dry eye syndrome (DES), in 35 patients (57.4%). The prevalence of DES in the control group was 21.3%. The proportion of DES in patients with IBD was significantly higher than in the control group (P=0.002).

Conclusions

Ophthalmologic manifestations were high (72.1%) in IBD patients. Clinically significant primary ocular inflammation occurred in 8.2% of patients. The most common complication was DES. There was a higher rate of DES in patients with IBD compared to the control group. Evaluation of the eye should be a routine component in patients with IBD.

Citations

Citations to this article as recorded by

Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Yakup Kilic, Shahed Kamal, Farah Jaffar, Danujan Sriranganathan, Mohammed Nabil Quraishi, Jonathan P Segal
Inflammatory Bowel Diseases.2024; 30(2): 230. CrossRef
Isoliquiritin Ameliorates Ulcerative Colitis in Rats through Caspase 3/HMGB1/TLR4 Dependent Signaling Pathway
Zhiwei Miao, Mingjia Gu, Faisal Raza, Hajra Zafar, Jianyi Huang, Yuhang Yang, Muhammad Sulaiman, Jing Yan, Yi Xu
Current Gene Therapy.2024; 24(1): 73. CrossRef
Use of Systemic Steroids for Inflammatory Bowel Disease Can Increase Intraocular Pressure
Amrik Gil, Madeline Alizadeh, Daniel Yarmovsky, Ramya Swamy, Uni Wong
Gastro Hep Advances.2024; 3(4): 536. CrossRef
Ocular lesions in patients with ulcerative colitis
Antonina V. Varvarynets, Valerii D. Beliayev, Mykhailo M. Hechko, Artur V. Kurakh
Wiadomości Lekarskie.2024; 77(3): 445. CrossRef
The risk for ophthalmological conditions in ulcerative colitis: A population‐based case–control study. Is silica dust‐exposure associated with inflammatory eye disease?
Karim Makdoumi, Lucyn Ayoub, Ing‐Liss Bryngelsson, Pål Graff, Pernilla Wiebert, Per Vihlborg
Acta Ophthalmologica.2024; 102(7): 828. CrossRef
Optical coherence tomography angiography findings of retinal vascular structures in children with celiac disease
Ishak Isik, Lutfiye Yaprak, Asli Yaprak, Ulas Akbulut
Journal of American Association for Pediatric Ophthalmology and Strabismus.2022; 26(2): 69.e1. CrossRef
Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era
Alix Cuny, Lucas Guillo, Cédric Baumann, Patrick Netter, Silvio Danese, Bénédicte Caron, Laurent Peyrin-Biroulet, Karine Angioi
Journal of Clinical Medicine.2022; 11(15): 4538. CrossRef
The Prevalence of Ocular Extra-Intestinal Manifestations in Adults Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Jing-Xing Li, Chun-Chi Chiang, San-Ni Chen, Jane-Ming Lin, Yi-Yu Tsai
International Journal of Environmental Research and Public Health.2022; 19(23): 15683. CrossRef
Ocular Manifestations of Inflammatory Bowel Disease
Janaki Shah, Aaditya Shah, Lynn Hassman, Alexandra Gutierrez
Inflammatory Bowel Diseases.2021; 27(11): 1832. CrossRef
Ocular manifestations of inflammatory bowel diseases: an update for gastroenterologists
Fabio CASTELLANO, Giovanni ALESSIO, Carmela PALMISANO
Minerva Gastroenterology.2021;[Epub] CrossRef
The Effectiveness of Probiotics in the Treatment of Inflammatory Bowel Disease (IBD)—A Critical Review
Dominika Jakubczyk, Katarzyna Leszczyńska, Sabina Górska
Nutrients.2020; 12(7): 1973. CrossRef
Les manifestations oculaires au cours de la maladie de Crohn
D. Saadouli, K. Ben Mansour, M. Farae, I. Loukil, S. Yahyaoui, M.A. El Afrit
Journal Français d'Ophtalmologie.2020; 43(10): 1025. CrossRef
Evaluation of Objective Signs and Subjective Symptoms of Dry Eye Disease in Patients with Inflammatory Bowel Disease
Zsolt Barta, Levente Czompa, Aniko Rentka, Eva Zold, Judit Remenyik, Attila Biro, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
BioMed Research International.2019; 2019: 1. CrossRef
The optimal time to perform an ophthalmic examination of patients with inflammatory bowel disease
Ana Luiza Biancardi, Leandro Lopes Troncoso, Haroldo Vieira de Moraes Jr, Cyrla Zaltman
Intestinal Research.2019; 17(1): 153. CrossRef
Current clinical issue of skin lesions in patients with inflammatory bowel disease
Tomoya Iida, Tokimasa Hida, Minoru Matsuura, Hisashi Uhara, Hiroshi Nakase
Clinical Journal of Gastroenterology.2019; 12(6): 501. CrossRef
Manifestaciones extraintestinales de enfermedad inflamatoria intestinal
Amaranta Luzoro, Pablo Sabat, Leonardo Guzmán, Francisca Frias
Revista Médica Clínica Las Condes.2019; 30(4): 305. CrossRef
Corneal Manifestations of Inflammatory Bowel Disease
Levente Czompa, Zsolt Barta, Hassan Ziad, Gabor Nemeth, Aniko Rentka, Zsuzsa Aszalos, Eva Zold, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
Seminars in Ophthalmology.2019; 34(7-8): 543. CrossRef

6,319 View
97 Download
19 Web of Science
17 Crossref

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study: Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi; Intest Res 2017;15(3):368-379. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.368

Abstract PDF PubReader ePub

Background/Aims

This study assessed the efficacy and safety of high-dose multimatrix mesalazine once-daily (QD) compared to another form of high-dose mesalazine.

Methods

In this multicenter, randomized, double-blind study, 280 patients with mildly to moderately active ulcerative colitis (UC) received multimatrix mesalazine 4.8 g/day QD or pH-dependent-release mesalazine 3.6 g/day three times daily for 8 weeks. The primary endpoint was the change in the UC-Disease Activity Index (UC-DAI) at the end of the treatment period.

Results

The change in the UC-DAI (mean±standard deviation) in the per-protocol set was −2.6±2.47 in the multimatrix mesalazine 4.8 g/day group (n=134) and −1.8±2.64 in the pH-dependent-release mesalazine 3.6 g/day group (n=129). The difference in the mean change between the 2 groups was −0.7 (two-sided 95% confidence interval, −1.3 to −0.1). The noninferiority of multimatrix mesalazine 4.8 g/day to pH-dependent-release mesalazine 3.6 g/day was verified within the noninferiority margin (1.1). The superiority of multimatrix mesalazine 4.8 g/day to pH-dependent-release mesalazine 3.6 g/day was also investigated and confirmed in the full analysis set, according to the study protocol. In subgroup analyses, the effectiveness of multimatrix mesalazine 4.8 g/day was consistent in all subgroups. There was no difference in safety between the 2 treatment groups.

Conclusions

Multimatrix mesalazine 4.8 g/day has higher efficacy and shows no difference in safety in mildly to moderately active UC, in comparison with pH-dependent-release mesalazine 3.6 g/day.

Citations

Citations to this article as recorded by

Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database
Takumi Ota, Takahiro Takebe, Yutaka Shimizu, Takashi Orido, Hiroyuki Tanaka, Shiro Nakamura
Digestion.2024; 105(3): 232. CrossRef
Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S‐methyltransferase inhibition
Hiromu Morikubo, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Satoshi Kuronuma, Osamu Takeuchi, Tenyo Shiba, Hiroki Kiyohara, Mao Matsubayashi, Shintaro Sagami, Masaru Nakano, Osamu Ikezaki, Tadakazu Hisamatsu, Yoichi Tanaka, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2021; 36(8): 2116. CrossRef
Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis
Tong Wang, Hua Lu, Fangyuan Li, Qi Zhang
Medicine.2021; 100(5): e23915. CrossRef
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef
Efficacy of Multi Matrix System Mesalazine for the Induction of Remission in Patients with Ulcerative Colitis who Insufficiently Respond toother Mesalazine Formulations: A Japanese Single-center Study
Masaki Kato, Kohei Sugiyama, Maki Miyakawa, Masanao Nasuno, Hiroki Tanaka, Satoshi Motoya
Nippon Daicho Komonbyo Gakkai Zasshi.2021; 74(6): 357. CrossRef
pH‑dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review)
Helmut Deissler, Heinrich Krammer, Anton Gillessen
Biomedical Reports.2021;[Epub] CrossRef
Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
Hiroshi Nakase
Gut and Liver.2020; 14(1): 7. CrossRef
Inflammatory Bowel Disease – Non-biological treatment
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
Pharmacological Research.2020; 160: 105075. CrossRef
Systematic review: safety of mesalazine in ulcerative colitis
P. Sehgal, J.‐F. Colombel, A. Aboubakr, N. Narula
Alimentary Pharmacology & Therapeutics.2018; 47(12): 1597. CrossRef

6,490 View
83 Download
8 Web of Science
9 Crossref

Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study: Haruhiko Ogata, Akihiro Ohori, Haruo Nishino, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi; Intest Res 2017;15(3):358-367. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.358

Abstract PDF PubReader ePub

Background/Aims

This study compared the efficacy of once-daily administration of multimatrix mesalazine 2.4 g/day with multiple-dose mesalazine for the maintenance of remission.

Methods

In this multicenter, randomized, double-blind study, 203 patients with ulcerative colitis in remission received multimatrix mesalazine 2.4 g/day once-daily or time-dependent (controlled-release) mesalazine 2.25 g/day 3 times-daily for 48 weeks. The primary efficacy endpoint was the proportion of patients without rectal bleeding.

Results

The proportion of patients without rectal bleeding during the 48-week treatment period in the per protocol set was 84.8% (84/99) in the multimatrix mesalazine 2.4 g/day group and 78.0% (78/100) in the controlled-release mesalazine 2.25 g/day group. The difference between the 2 treatment groups was 6.8% (two-sided 95% confidence interval, −3.9% to 17.6%). The noninferiority margin of −10% was met in the comparison of multimatrix mesalazine 2.4 g/day once-daily with controlled-release mesalazine 2.25 g/day. Multimatrix mesalazine 2.4 g/day once-daily demonstrated consistent efficacy in all subgroups. There was no difference between the 2 treatment groups with regard to safety.

Conclusions

A once-daily dose of 2 multimatrix mesalazine tablets (2.4 g) was not inferior to controlled-release mesalazine 2.25 g/day 3 times-daily in maintaining absence of rectal bleeding in ulcerative colitis.

Citations

Citations to this article as recorded by

A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation
Masahiro Kishi, Fumihito Hirai, Noritaka Takatsu, Takashi Hisabe, Yasumichi Takada, Tsuyoshi Beppu, Ken Takeuchi, Makoto Naganuma, Kazuo Ohtsuka, Kenji Watanabe, Takayuki Matsumoto, Motohiro Esaki, Kazutaka Koganei, Akira Sugita, Keisuke Hata, Kitarou Fut
Journal of Gastroenterology.2022; 57(4): 246. CrossRef
Inflammatory Bowel Disease – Non-biological treatment
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho
Pharmacological Research.2020; 160: 105075. CrossRef
Systematic review: safety of mesalazine in ulcerative colitis
P. Sehgal, J.‐F. Colombel, A. Aboubakr, N. Narula
Alimentary Pharmacology & Therapeutics.2018; 47(12): 1597. CrossRef
How to Optimally Use Currently Available Drugs in a Therapeutic Algorithm?
You Sun Kim
The Korean Journal of Gastroenterology.2018; 71(2): 74. CrossRef

5,569 View
60 Download
3 Web of Science
4 Crossref

Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease: Daniéla Oliveira Magro, Paulo Gustavo Kotze, Carlos Augusto Real Martinez, Michel Gardere Camargo, Dioze Guadagnini, Antonio Ramos Calixto, Ana Carolina Junqueira Vasques, Maria de Lourdes Setsuko Ayrizono, Bruno Geloneze, José Carlos Pareja, Mario José Saad, Claudio Saddy Rodrigues Coy; Intest Res 2017;15(3):352-357. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.352

Abstract PDF PubReader ePub

Background/Aims

Lipopolysaccharide (LPS) is a molecule formed by lipids and polysaccharides and is the major cell wall component of gram-negative bacteria. High LPS levels are known to block CD26 expression by activating Toll-like receptor 4. The aim of this study was to correlate the serum levels of LPS and CD26 in Crohn's disease (CD) patients with serum levels of C-reactive protein (CRP), interleukins, CD activity index, and tumor necrosis factor-α (TNF-α).

Methods

Serum samples were collected from 27 individuals (10 with active CD, 10 with inactive CD, and 7 controls) and the levels of LPS, CD26, TNF-α, interleukin-1β (IL-1β), IL-6, IL-17, and CRP were determined by enzyme-linked immunosorbent assay. The levels of LPS and CD26 were then tested for correlation with TNF-α, IL-1β, IL-6, IL-17, and CRP.

Results

Serum levels of LPS were significantly elevated in the active CD group (P=0.003). Levels of IL-1β (P=0.002), IL-6 (P=0.003), and IL-17 (P<0.001) were lower in the CD groups. Serum TNF-α levels were increased in the active CD group. The CRP levels were elevated in the CD groups when compared to controls (P<0.001). The CD26 levels were lower in the CD groups than in the control group (P<0.001). Among the variables analyzed, there was a correlation between LPS and CRP (r=−0.53, P=0.016) in the CD groups.

Conclusions

Individuals with CD exhibited higher serum levels of LPS varying from a 2- to 6-fold increase depending on disease activity, when compared with healthy controls. CD26 levels were lower in the CD groups. Both LPS and CD26 correlated with disease severity and serve as potential CD biomarkers.

Citations

Citations to this article as recorded by

ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Ondřej Kučerka, Martin Malý, Petra Mináriková, Jan M. Horáček
Military Medical Science Letters.2024;[Epub] CrossRef
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
Kashif Rahim, Muhammad Shan, Ihtisham Ul Haq, Muhammad Nawaz, Sajida Maryam, Mansour Alturki, Abdulaziz Al Khzem, Kamel Metwally, Simona Cavalu, Saleh Alqifari, Galal Yahya
Journal of Inflammation Research.2024; Volume 17: 1897. CrossRef
Interaction between diet and genetics in patients with inflammatory bowel disease
Daniéla Oliveira Magro, Ligia Yukie Sassaki, Júlio Maria Fonseca Chebli
World Journal of Gastroenterology.2024; 30(12): 1644. CrossRef
Quantitative urinary proteome analysis reveals potential biomarkers for disease activity of Behcet’s disease uveitis
Weiwei Qin, Anyi Liang, Xiaoxu Han, Meifen Zhang, Youhe Gao, Chan Zhao
BMC Ophthalmology.2024;[Epub] CrossRef
Dietary fat induced chylomicron-mediated LPS translocation in a bicameral Caco-2cell model
Monic M. M. Tomassen, Coen Govers, A. Paul Vos, Nicole J. W. de Wit
Lipids in Health and Disease.2023;[Epub] CrossRef
Endothelial Glycocalyx Preservation—Impact of Nutrition and Lifestyle
Paula Franceković, Lasse Gliemann
Nutrients.2023; 15(11): 2573. CrossRef
Toll-like Receptors and Cytokine Modulation by Goat Milk Extracellular Vesicles in a Model of Intestinal Inflammation
Chiara Grazia De Ciucis, Floriana Fruscione, Livia De Paolis, Samanta Mecocci, Susanna Zinellu, Lisa Guardone, Giulia Franzoni, Katia Cappelli, Elisabetta Razzuoli
International Journal of Molecular Sciences.2023; 24(13): 11096. CrossRef
Longitudinal flux balance analyses of a patient with episodic colonic inflammation reveals microbiome metabolic dynamics
Arianna Basile, Almut Heinken, Johannes Hertel, Larry Smarr, Weizhong Li, Laura Treu, Giorgio Valle, Stefano Campanaro, Ines Thiele
Gut Microbes.2023;[Epub] CrossRef
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice
Rachele Gore, Mitra Mohsenipour, Jennifer L. Wood, Gayathri K. Balasuriya, Elisa L. Hill-Yardin, Ashley E. Franks, Manuela Raffatellu
Infection and Immunity.2023;[Epub] CrossRef
MEFV and NLRP3 Inflammasome Expression Is Attributed to Immature Macrophages and Correlates with Serum Inflammatory Proteins in Crohn´s Disease Patients
Frida Gorreja, Charles Caër, Stephen T. A. Rush, Sophia K. Forsskål, Anetta Härtlova, Maria K. Magnusson, Elinor Bexe Lindskog, Lars G. Börjesson, Mattias Block, Mary Jo Wick
Inflammation.2022; 45(4): 1631. CrossRef
Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease
Jie Huang, Xinxin Liu, Yingying Wei, Xinlu Li, Shupei Gao, Lingli Dong, Xiaoquan Rao, Jixin Zhong
Frontiers in Immunology.2022;[Epub] CrossRef
Genetic Deletion of LRP5 and LRP6 in Macrophages Exacerbates Colitis-Associated Systemic Inflammation and Kidney Injury in Response to Intestinal Commensal Microbiota
Indumathi Manoharan, Daniel Swafford, Arulkumaran Shanmugam, Nikhil Patel, Puttur D. Prasad, Riyaz Mohamed, Qingqing Wei, Zheng Dong, Muthusamy Thangaraju, Santhakumar Manicassamy
The Journal of Immunology.2022; 209(2): 368. CrossRef
The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review
Francisco Jorge Melo, Pedro Pinto-Lopes, Maria Manuela Estevinho, Fernando Magro
Inflammatory Bowel Diseases.2021; 27(7): 1153. CrossRef
Effects of Anthocyanin on Intestinal Health: A Systematic Review
Thaísa Agrizzi Verediano, Hércia Stampini Duarte Martino, Maria Cristina Dias Paes, Elad Tako
Nutrients.2021; 13(4): 1331. CrossRef
Anti-inflammatory activity of Jasminum grandiflorum L. subsp. floribundum (Oleaceae) in inflammatory bowel disease and arthritis models
Riham A. El-Shiekh, Dorria Hussein, Attia H. Atta, Samar M. Mounier, Mohamed R. Mousa, Essam Abdel-Sattar
Biomedicine & Pharmacotherapy.2021; 140: 111770. CrossRef
Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management
Jasmijn A. M. Sleutjes, Jeanine E. Roeters van Lennep, C. Janneke van der Woude, Annemarie C. de Vries
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease
Sabrina A Fernandes, Carina Rossoni, Vivian W Koch, Marcello Imbrizi, Rosana Evangelista-Poderoso, Letícia Pereira Pinto, Daniéla Oliveira Magro
Artificial Intelligence in Gastroenterology.2021; 2(4): 111. CrossRef
Correlation between Antibodies to Bacterial Lipopolysaccharides and Barrier Proteins in Sera Positive for ASCA and ANCA
Aristo Vojdani, Elroy Vojdani, Martha Herbert, Datis Kharrazian
International Journal of Molecular Sciences.2020; 21(4): 1381. CrossRef
CD26/DPP4 - a potential biomarker and target for cancer therapy
Njanja Enz, Gwendolyn Vliegen, Ingrid De Meester, Wolfgang Jungraithmayr
Pharmacology & Therapeutics.2019; 198: 135. CrossRef
Is there a possible correlation between antibodies against lipopolysaccharide, intestinal and blood-brain barrier proteins in IBD subjects?
Aristo Vojdani
Autoimmunity Reviews.2019; 18(6): 639. CrossRef
CD26 in autoimmune diseases: The other side of “moonlight protein”
Yunjuan Zhao
International Immunopharmacology.2019; 75: 105757. CrossRef
Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production
Daniéla Oliveira Magro, Andrey Santos, Dioze Guadagnini, Flavia Moreira de Godoy, Sylvia Helena Monteiro Silva, Wilson José Fernandes Lemos, Nicola Vitulo, Sandra Torriani, Lilian Vital Pinheiro, Carlos Augusto Real Martinez, Mario José Abdalla Saad, Clau
Scientific Reports.2019;[Epub] CrossRef
Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults
Tiansheng Wang, Jeff Y. Yang, John B. Buse, Virginia Pate, Huilin Tang, Edward L. Barnes, Robert S. Sandler, Til Stürmer
Diabetes Care.2019; 42(11): 2065. CrossRef
Emerging concepts in non-invasive monitoring of Crohn’s disease
Wojciech Marlicz, Karolina Skonieczna-Żydecka, Konstantinos John Dabos, Igor Łoniewski, Anastasios Koulaouzidis
Therapeutic Advances in Gastroenterology.2018;[Epub] CrossRef
VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN’S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS
Daniéla Oliveira MAGRO, Maria Rita Lazzarini BARRETO, Everton CAZZO, Michel Gardere CAMARGO, Paulo Gustavo KOTZE, Claudio Saddy Rodrigues COY
Arquivos de Gastroenterologia.2018; 55(2): 142. CrossRef

6,240 View
54 Download
24 Web of Science
25 Crossref

First
Prev
Page of 17
Next
Last

Original article